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1 Abbreviations 
 
AAV – Adeno-associated Virus 
ACAID – Anterior-chamber-associated Immune deviation 
AMD – Age related Macular Degeneration 
a-MSH – a-melanocyte stimulating hormone 
APC – Antigen presenting cell 
CGRP – calcitonin gene-related peptide 
EAU – Experimental autoimmune uveoretinitis 
EMA – European Medical Agency 
FC – Fold change 
GFAP – Glial fibrillary acidic protein 
GFP – Green fluorescent protein 
INF – interferon  
ITR – inverted terminal repeat 
LCA – Lebers Congenital Amaurosis 
NHP – non human primate 
NK cell – natural killer cell 
NKT cell – natural killer T cell 
NOD – nucleotide-binding oligomerization domain 
OCT – optical coherence tomography 
PAMP – pathogen-associated molecular pattern 
PE cell – pigment epithelium cell 
PFA - paraformaldehyde 
PRR – pattern recognition receptors 
RIG – retinoic acid inducible gene 1 
RP – Retinits Pigmentosa 
TGFb - transforming growth factor b 
TSP - thrombospondin 
VIP – vasoactive intestinal peptide 
XLRS – X-linked retinoschisis
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2 Introduction 
 
 
 Aim of the study 
 
Adeno-associated viral vector (AAV) have established themselves as powerful tools for 
retinal gene therapy. Multiple clinical trials have shown that AAV mediated gene 
therapies can be safely administered to the subretinal space, efficiently deliver the 
therapeutic gene to the cells of the retina and ultimately improve the visual function of 
the patient. 
The safety of the AAV mediated ocular gene therapy has been attributed to the non-
immunogenic properties of AAV and the special anti-inflammatory mechanisms that 
constitute the immune privilege of the eye. 
This assumption is recently being challenged by an increasing number of clinical trials 
reporting cases of intraocular inflammation following AAV mediated gene therapy 
treatment. These findings suggest that the immune privilege mechanisms of the eye can 
be overstressed and evoke the question whether the immunogenic potential of AAV has 
been underestimated. Although the inflammation was in most cases manageable under 
steroid treatment, in some cases the local immune response not only impaired the 
treatment effect but lead to a decline of visual function of the patient1, 2.  
Preventing these serious adverse events is of highest interest to patients and researches 
alike. To do this, a profound understanding of the immune response is essential. However, 
although the ocular immune privilege has been studied intensively, many questions 
remain unanswered and little is known about how the retinal immune system reacts upon 
the contact with AAV. It is unclear which part of the vector particle leads to inflammation, 
how the vector is sensed by the innate immunity and which cells are involved in the 
immune reaction.  
It was therefore the aim of this dissertation to shed a light on the mechanisms of the ocular 
immune response to subretinal AAV8. 
To elucidate the mechanisms involved in AAV immunity, we used the data and the 
material of a study that was primarily designed as a good laboratory practice (GLP) 
conform toxicology and biodistribution study for an investigational new drug (IND) 
application with the national competent authority (Paul Ehrlich Institute). Data from 
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nonhuman primates that were treated with different doses of subretinal und intravitreal 
AAV8 were compared to clinical data from three patients treated with the same vector. 
In order to approach different aspects of AAV immunity, several assays were used: 
Systemic humoral immunity was assessed by capsid-antigen ELISA and the local 
immune response was investigated by immunohistochemistry. To study the local immune 
response on a molecular level, an expression profile of whole retinal tissue was 
conducted. This gene assay included receptor molecules as well as downstream proteins 
of the different signaling pathways.  
In this study we present data suggesting that AAV8 is sensed by innate antiviral receptors 
and activates immune competent cells of the innate and adaptive immune system in the 
retina. This study will guide future investigators in conducting studies to enhance safety 
and efficacy of AAV vector mediated gene therapies.  
 
 
 Gene therapy overview and short history 
 
The general concept of gene therapy is to deliver a therapeutic nucleic acid into a target 
cell in order to treat the genetic condition that is causing the disease.  
This concept promises a very elegant treatment solution for many genetic diseases. 
Moreover, it offers a one-shot treatment option for diseases where otherwise no treatment 
option is at hand or only extensive and time-consuming treatments are available. As 
appealing as this concept is, as many difficulties are there to face in order to develop such 
a treatment option. Challenges in gene therapy are the immune response to foreign bodies 
like viral vectors, the (limited) transduction efficiency, the (limited) specificity to the 
target cells and the need for a long-lasting treatment effect.  
These multiple obstacles require a spectrum of different approaches comprised in the term 
“gene therapy”.  
For example, gene therapy concepts can be divided into in vivo and ex vivo concepts. In 
vivo gene therapy is a concept where vector particles are injected into the blood stream 
or directly into to the diseased tissue. In ex vivo gene therapy the target cells are treated 
in vitro and afterwards reinfused into the patient’s body.  
Other differences exist in the function of the nucleic acid. Currently, most gene therapy 
strategies in the clinical setting introduce a healthy copy of the affected gene into the 
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target cell, a strategy dubbed gene augmentation therapy. This works well for recessive 
gene mutations with a reduced or complete loss of function of the affected gene. For 
dominant or more complex genetic diseases new concepts exist that use nucleic acids for 
silencing or editing genetic expression.  
A third category by which gene therapies can be divided by is the delivery system of the 
therapeutic nucleic acid into the target cell. With respect to the delivery system, two broad 
categories exist: Nonviral physico-chemical approaches and recombinant viral vectors. 
Viral vectors like AAV are currently the most popular approach and account for more 
than two thirds of all gene therapy trials today.3 The popularity of viral vectors derives 
from their superior stability and efficacy in transducing target cells compared to nonviral 
vectors. The most commonly used viral vectors are adenoviral, retroviral and adeno-
associated viral vectors (AAV).3 Synthetical nonviral vectors, on the other side, offer 
lower risk of immunogenicity, no risk of mutagenesis, easier synthesis and greater 
capacities in packaging large molecules.4 Nonviral vectors are most often naked plasmids 
or less often liposomal molecules.  
All these different approaches have evolved in a period of around 40 years5. The 
translation to patient care came in 1990 when the FDA approved the first viral vector 
mediated gene therapy trial in humans. Two children with adenosine desaminase 
deficiency (ADA-SCID) were treated effectively and without severe adverse effects with 
a retroviral vector.6 
The euphoria that these results created led to an expansion of the field. In the following 
years trials followed for other primary immune deficiencies7, for lipoprotein-lipase-
deficiency8, hemophilia B9 and Beta-hemoglobinopathy.10 By 2018, 2300 gene therapy 
trials have been completed, are ongoing or approved worldwide.3 The first commercially 
available gene therapy was approved for therapy by the EMA in 2012: an AAV based 
gene therapy for lipoprotein-lipase-deficiency, called Glybera, was the first gene therapy 
that made the way from bench to bedside.11  
However, the optimism of the field was also repeatedly dampened by disappointing 
clinical trial results. The following 2 events of uncontrolled immune responses and 
carcinogenesis were major setbacks in gene therapy development.  
10 years after the FDA had approved the therapy for ADA-SCID, another study using a 
retroviral vector for a similar disease, X-linked severe combined immunodeficiency 
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(SCID-X1) was enrolled and initially presented sustained correction of the 
immunodeficiency. In the 2-year follow-up though, the group had to report that the risk 
of insertional mutagenesis by the retroviral vector had been underestimated and 2 out of 
the 10 treated children had developed a leukemia-like syndrome.12  
In a similar way, the risk of viral vectors eliciting a vigorous immune response was 
underestimated with tragic effects, when the 18-year-old patient Jesse Gelsinger died of 
systemic inflammatory response syndrome after adenoviral (AdV) gene transfer.13  
These examples illustrate the importance of further research to ensure safety in viral 
vector mediated gene therapy development. Although recombinant AAV (rAAV) carries 
a dramatically decreased risk of insertional mutagenesis than retroviral vectors and is less 
immunogenic than adenovirus (AdV) the broad use of rAAV in multiple clinical studies 
and accumulating reports of inflammatory responses1, 2 highlight the relevance of this 
research area. 
 
 
  Ocular gene therapy  
 
The eye has been at the forefront of gene therapy development for the following reasons: 
a) for blinding disorders like inherited retinal degenerations no or only insufficient 
medical treatment is at hand b) the eye as a bilateral organ offers a perfect internal control 
and is easily accessible for therapeutics and diagnostics c) the eye is immune-privileged, 
described first by Medawar in 194814 and therefore regarded as a relatively safe space to 
administer a foreign body like a virus.  
The need for treatment options for inherited retinal degenerations is highlighted by the 
fact that, although the individual diseases are quite rare, as a group of disorders they affect 
over 2 million people worldwide.15 In contrast to multigenic and multifactorial diseases 
like AMD, inherited retinal diseases are of monogenetic origin and therefore the optimal 
basis for gene replacement therapies. Another precondition for the advancement of ocular 
gene therapy development was the pace of scientific discovery of the underlying genetic 
mechanisms, made possible by the enormous technical development in genetic 
sequencing. In 1990, for the first time a point mutation in the rhodopsin gene for a form 
of retinitis pigmentosa (RP) was described.16 Today the number of genes known to cause 
retinal diseases has risen to over 300 (RetNet: https://sph.uth.edu/retnet/) 
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Targeted monogenetic diseases include Leber’s congenital amaurosis (LCA), 
Choroideremia, Achromatopsia, juvenile X-linked Retinoschisis, Stargardt disease, and 
other forms of RP.17 
Since all of these diseases affect the retina, basically two different options exist for the 
application of ocular gene therapies: The vector solution can either be delivered to the 
retina by a subretinal or an intravitreal injection. For the subretinal delivery, a pars plana 
vitrectomy is performed, followed by the injection of around 200µl of volume into the 
subretinal space where a small bleb is created by the injection. The intravitreal injection 
on the other side is performed like the common intravitreal injection of medications for 
diseases like AMD. However, it was shown in the animal model that when cells of the 
outer retina are targeted, intravitreal injections are not as successful in restoring retinal 
function.18 As reviewed by Gupta et al.17, with one exception, all active and completed 
gene therapy trials for retinal degeneration by the end of 2017, used the subretinal 
approach.  
The advantage of the subretinal approach is the intraoperatively vision-guided selection 
of treatment area and the proximity of vector solution to RPE and outer retina. 
Nevertheless, subretinal injections are the more complicated procedure with the inherent 
risks of temporary retinal detachment19. Complications like a macular hole formation, 
unresolved retinal detachment, choroidal effusions and the loss of foveal thickness have 
been described by the RPE65 trials20-22. Methods like the two-step procedure originally 
described by Bainbridge et al.23, or intraoperative OCT24 help to minimize the trauma of 
subretinal injections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene therapy application through pars-plana injection into A the subretinal space between 
photoreceptors and the RPE and B into the intravitreal cavity.  
Figure from Ochakovski et al.25 
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The first promising results for retinal gene therapy came from the RPE65 studies targeting 
Leber’s congenital amaurosis (LCA). This condition was first described by Theodor 
Leber in the 19th century as a severe blinding disorder that accounts for 5% of all inherited 
retinal dystrophies. The mutation in the gene RPE65 was identified in humans suffering 
of LCA in 199726. Veske et al.27 discovered only two years later that the blinded Briard 
dog28 was also carrying a mutation in the canine homologue of RPE65. After it had been 
demonstrated that the Rpe65 mutated Briard dog could effectively be treated with an 
AAV2 virus carrying the healthy RPE65 gene18, in 2008 three groups published initial 
reports of clinical trials in LCA patients using the same strategy. While functional gain 
in the treated patients was limited, no serious adverse events or systemic side effects were 
observed. 20, 22, 23, 29 The excitement that these results provoked gave the basis for future 
studies to follow. The scientific progress culminated in the first phase 3 study being 
successfully completed in 2017 and the approval of the first ocular gene therapeutic 
product for LCA by the FDA in 2018.30 
However, the long-term follow-up of the LCA patients1, 21, 31 also revealed the challenges 
of ocular gene therapies. Major challenges are efficacy and the longevity of the effect. 
The immune response was in general mild and manageable and will be discussed in more 
detail in the section “Immune response to AAV”. In terms of efficacy the results 
somewhat varied. Whereas one group could report a gain in visual acuity for up to three 
years32, the other groups could not show beneficial treatment effects in visual acuity but 
improved outcome measures of retinal sensitivity like microperimetry or pupillary 
responses1, 21. Concerning the longevity of effect, in the long-term follow up, the 
observation was made by several groups, that although function can be improved after 
injection, the degeneration of the retina is not necessarily abated and continues over the 
following years.1, 33, 34 Functional benefits were found to decline after 4.5-6 years34.  
When looking into new target genes, a more general challenge of gene therapy which is 
not restricted to diseases of the eye, are the limitations imposed by the gene itself. The 
clinical trials of today rely on gene replacement of a nonfunctional protein. In cases where 
a mutation leads to a truncated protein with a negative effect on the functional protein, 
simple gene augmentation or replacement strategies may be insufficient. Here, new 
techniques of genome editing come into play that might be able to provide a solution for 
the treatment of these mutations in the future.  
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Secondly, the selection of target genes is limited through the packaging size of the 
delivery system. The AAV capsid is able to accommodate a 4.7kb genome. Techniques 
to overcome this problem are the use of viral vectors with larger capacity like lentiviruses, 
the minimization of promotors35 or the simultaneous co-transduction with dual AAVs36 
with the aim of homologous recombination of overlapping nucleotide sequences. 
 
 
   Adeno-associated virus as vector 
 
In order to introduce DNA into the host cell, the DNA molecule has to be protected from 
degradation before reaching the cell, then cross the cell membrane and escape the cells 
internal defense mechanisms to successfully advance into the cell nucleus. Synthetic 
nonviral particles are able to effectively transfect cells in-vitro but show minor efficiency 
in in-vivo experiments. Viruses, like AAV, have evolutionally perfected their capability 
to introduce their genome into the host cell over millions of years and are therefore 
regarded as highly effective and promising vectors for gene therapy.37 
AAV was discovered in 1965 as a virus particle that can be found in the presence of an 
adenovirus but is itself replication defective.38, 39 Because of its dependency on 
adenovirus to replicate, it was titled Adeno-associated virus. AAV belongs to the family 
of Parvoviridae, has a small non-enveloped icosahedral capsid and is about 25nm in 
diameter. In the last 50 years AAV became more and more experimentally characterized: 
different serotypes were identified40, the 4.7 kb ssDNA was identified as the genome of 
AAV41 and the two palindromic sequences flanking the genome, called inverted terminal 
repeats (ITR), were identified as the origin of genome replication.42-44 Apart from the 
ITRs, the wildtype AAV genome encodes for four proteins required for replication called 
Rep Proteins, three capsid proteins (VP1-3) and the assembly-activating protein (AAP)45. 
In the absence of Adenovirus, AAV can persist in the cell in a latent stage.46 This 
discovery led to the idea for the use of AAV in gene therapy. 
For gene therapy the Rep and Cap genes are removed from the AAV genome and replaced 
by what is called a “transgene expression cassette” flanked only by the ITRs on each 
side.47 The transgene expression cassette contains a promotor sequence and the open 
reading frame defined by the transgene. The selection of the promotor is carefully done 
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by the investigator, as the expression varies according to the different host cell types and 
its size impacts on the space left for the therapeutic gene.  
A common production process for a recombinant AAV vector is to transfect HEK293 
cells with three plasmids, one containing the transgene expression cassette flanked by the 
ITRs, one containing the rep and cap genes and another plasmid containing genes from 
adenovirus necessary for replication. 
The cap genes define the capsid protein structure and the resulting serotype. The 
definition of a unique serotype is a virus that cannot be recognized by neutralizing 
antibodies generated against another serotype of the virus.48 Pioneering work for the use 
of AAV in gene therapy was done with the serotype 2.49 
Until today at least 13 different serotypes have been described and each of these serotypes 
presents a specific cell tropism.50 The serotype can be purposefully selected to enhance 
transduction efficiency in the target cells. For example, AAV2, is very efficient in 
transducing RPE cells of the retina, a reasons for which it is used by the initial ocular 
gene therapy trials for RPE65 - LCA.51 When targeting photoreceptors though, at least in 
the monkey retina, AAV8 for example was shown to be superior to AAV2.51  
Further on, the efficiency and the tissue tropism can be enhanced by combining the 
genome from one serotype with the capsid from another, a process called 
“pseudotyping”.52, 53 Pseudotyped vector AAV2/5 for example is composed of the 
genome from AAV2 and the capsid from AAV5 and has been found to be very specific 
to the outer nuclear layer of the human retina.54  
The uptake of AAV into the cells is mediated by various receptor molecules. The first to 
be described was heparan sulfat proteoglycan. This membrane-bound glycan facilitates 
the uptake of AAV255. Different glycans were found to be responsible for other serotypes 
and various co-receptors were described.56 In 2016 a universal AAV receptor (AAVR) 
was identified to serve multiple serotypes.57 The relationship between all these receptors 
remains unknown.56 After binding, AAV is internalized by endocytosis. This can happen 
in a clathrin-dependent or -independent manner58, 59.  
In the next step, endosomal escape is mediated by endosomal processing that involves 
conformational changes where the N-terminal domains of the VP1 and VP2 capsid 
protein are externalized.60, 61 The complete vector particle then passes the nucleus 
membrane, followed by uncoating and genome release.62  
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Once in the nucleus the genome uses the host cells translational machinery to produce the 
viral proteins or in the case of rAAV, the transgenic protein. This process does not 
demand an integration into the host cells genome. Only approximately 0.1% of wild type 
AAV genomes integrate63, 64, whereas the rest persists as double stranded episomal 
concatamers.65 This integration rate is much lower in case of recombinant AAV particles 
utilized for clinical gene therapy as explained below.  
In the case of dividing target cells, non-integration constitutes the disadvantage of 
genomic dilution as each daughter cell only inherits half of the non-integrated transgene 
copies. At the same time, lack of integration reduces the risk of mutagenic insertions. All 
available data show that the carcinogenic potential of recombinant AAV is extremely 
low, but is probably not zero. It is known that wildtype AAV integrates preferably on the 
AAVS1 site on chromosome 19 by an active Rep binding element of AAVS163, 64. 
Recombinant AAV vectors, which are not provided with the Rep gene, can not integrate 
via the Rep binding element of AAVS1 but are able to integrate via non-homologous 
integration at sites of DNA damage or very specifically at homologous locations66. It has 
been shown in the mouse model that in some situations recombinant AAV can induce 
hepatocellular carcinoma by integrational mutagenesis, although this has never been 
observed in other animal models or humans67.  
 
 
  Innate and adaptive immune response 
 
Our immune system is a complex network of different defence mechanisms against 
pathogenic organisms like viruses, bacteria, fungi and parasites. Two broad categories of 
defence lines can be theoretically distinguished from another although they interact over 
multiple ways.  
The innate immune response acts quickly, non-specific and does not generate 
immunological memory. It consists of anatomical barriers, antimicrobial proteins, the 
complement system and non-specific immune cells. The cells, mostly from the myeloid 
lineage, comprise macrophages, granulocytes, mast cells and dendritic cells. They are 
important sensor cells that express pattern recognition receptors (PRRs) which recognize 
foreign structures on the molecular surface of invading pathogens, also called pathogen-
associated molecular patterns (PAMPs). Members of the PRRs are the transmembrane 
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proteins like the Toll-like receptors (TLRs) that sense extracellular or endo-vesicular 
foreign pathogens, or cytoplasmic proteins like the retinoic acid inducible gene 1 (RIG)-
like and the nucleotide-binding oligomerization domain (NOD) -like receptors which 
have the ability to detect intracellular invasion of pathogens. The recognition of PAMPs 
by the PRRs leads over various signalling pathways to the activation of NFkB (nuclear 
factor kB) and interferon regulatory factors (IRFs) which are essential for the release of 
mediators like pro-inflammatory cytokines and chemokines. Cytokines are a way of 
communication between different immune cells and a connecting element to the adaptive 
immune response. Chemokines act as chemoattractants, guiding cells from the 
bloodstream to the infected tissue. Viral infection induces the production of cytokines 
called interferons (INF). Interferons can be distinguished into Type 1 (INF-a, INF-b) and 
Type 2 (INF-g). Type 1 Interferons are released by many cell types after viral infection 
and lead to the induction of antiviral host cell activity, increased MHC class I expression 
and antigen presentation, activation of dendritic cells, macrophages and NK-cells. The 
antiviral host cell activity is mediated by Interferon-stimulated genes (ISG). Known 
antiviral ISGs are for example the Mx protein, which sequesters viral ribonucleoproteins, 
the proteinkinase R, which inhibits viral protein translation and OAS proteins that 
degrade viral RNA via the activation of Rnase L68.  
The presentation of viral antigens via MHC class I makes the infected cells susceptible to 
being killed by CD8 cytotoxic T cells of the adaptive immune response. 
The adaptive immune response needs time to develop but is more efficient in eliminating 
a specific pathogen and has the ability to establish immunological memory.  
When an antigen is presented for the second time, the immunological memory allows the 
adaptive immune response to launch a much faster immune response. The adaptive 
immune response consists of antigen-specific lymphocytes. Two major different types of 
lymphocytes exist: B- and T-Lymphocytes. B-lymphocytes or B cells will proliferate and 
differentiate into antibody - producing Plasma cells after contact with their antigen. When 
a T-lymphocyte or T cell recognizes its specific antigen, the T cell will proliferate and 
differentiate into different effector subtypes, like cytotoxic T cells (CD8 positive), helper 
T cells (CD4 positive) and regulatory T cells. Cytotoxic T cells kill infected host cells, 
helper T cells support other immune cells like antibody producing B cells and regulatory 
T cells are able to suppress the activity of other immune cells. The CD4 T helper cell can 
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further by divided into Th1 and Th2 cells. Th1 cells can be characterized by the 
production of INF-g whereas Th2 cells mainly produce IL4 und 5. INF-g, also produced 
by NK-cells and cytotoxic CD8 T cells is responsible for the classical activation of 
macrophages and is able to increase the expression of and the antigen presentation via 
MHC Class I and II.  
Introduction 
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   Immune response of the eye 
 
An immune response in the eye can be especially deleterious to the important sensory 
function of vision, as it can lead to opacities in any of the transparent structures or induce 
irreparable injury to the non-dividing cells of the retina. For this reason, the human body 
has developed a complex array of immune mechanisms that protect the eye against 
pathogens without intense and destructive inflammation. Structures like the cornea and 
lens are therefore poorly vascularized, lymphatic drainage of the eye is limited and the 
blood ocular barrier is preventing unselective exchange of molecules.  
The blood ocular barrier features two components: the blood – aqueous barrier and the 
blood-retina barrier. The blood -aqueous barrier is formed by the non-pigmented layer of 
the ciliary body epithelium (PE) and by the endothelium of irideal capillaries.69 The 
blood-retinal barrier is divided into the inner blood retina barrier, made up of adherens- 
and tight-junctions between the endothelial cells of the capillaries and the outer blood 
retina barrier composed of similar junctions between the RPE cells.70 
Apart from these anatomical features, the eye has been found to exhibit a special down-
regulatory immune environment. Peter Medawar who observed prolonged survival of 
tissue grafts placed into the anterior chamber of the eye was the first to describe this 
immune privilege.14 The so called Anterior-chamber-associated Immune deviation 
(ACAID) was later extended to the intravitreal and subretinal space as well71, 72. The 
mechanisms that constitute this privileged immune response include anti-inflammatory 
molecules and immune suppressive cells.  
The ocular-splenic axis of the ACAID involves antigen presenting cells (APCs) that leave 
the eye despite the absence of draining lymphatics and circulate to the spleen where 
specific tolerance against the presented antigen is induced. Once arrived in the spleen, the 
APCs, together with joining natural killer T cells (NKT cells) and B cells orchestrate the 
deviant systemic immune response by inducing antigen specific regulatory T cells. The 
regulatory T cells (Treg), positive for CD25 and FoxP3, can be of the CD4 “afferent” or 
the CD8 “efferent” type. They suppress the induction of a Th1 and Th2 cell response and 
inhibit B cells from switching to complement binding immunoglobulin isotypes. The 
delayed-type hypersensitivity (DTH) reaction to the introduced antigen is supressed. 
Locally, an intraocular immunosuppressive microenvironment of TGF-b2, a-MSH, VIP, 
TSP, CGRP and MIF promotes the immune privilege by modulating the T cells into Treg 
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cells, preventing T cells to secrete INF-g, suppress NK cell function and inhibit the 
production of nitric oxide by activated macrophages73. 
Ocular resident cells like PE cells of the iris or the retina possess the ability to actively 
convert effector T cells into regulatory T cells via the secretion of TGF-b2, TSP and 
cytotoxic T-lymphocyte-associated antigen 2a (CTLA2a)74. 
Beside the soluble immunosuppressive factors, membrane bound CD95L or FasL is 
expressed on all parenchymal cells in the eye and triggers the death of invading immune 
cells75.  
Despite these mechanisms there seems to be a difference between the intravitreal and the 
subretinal space in terms of antigen presentation to the host immune system that favours 
the subretinal space: Preclinical NHP  studies with AAV mediated gene therapy for AMD 
and Leber’s hereditary optic neuropathy have shown that intravitreal administered vector 
solutions can lead to mild and moderate inflammation at dose (2.4 x10^10 vg/ml) that is 
relatively low when compared to doses given in subretinal studies76. Secondly, animal 
studies in mice and NHP have shown that successful intravitreal or subretinal re-
administration of vector is blocked by NABs after initial intravitreal but not after 
subretinal application77, 78.  
 
 
 Immune response to rAAV  
 
Generally, AAV is considered to be well-tolerable. In contrast to Adenovirus, which was 
also tested for retinal gene therapy but given up for its immunogenicity79, AAV has been 
safely administered to the human subretinal space in various clinical trials.  
Although epidemiological studies have shown that depending on serotype and country 
30-80% of the population have been in natural contact with the ubiquitous virus AAV80, 
the wtAAV has never been associated with any disease.  
On the other hand, recombinant AAV vectors are known to be sensed by the innate 
immune system and have been observed to elicit adaptive humoral and cellular immune 
responses capable of inhibiting successful therapy. The immunogenicity of rAAV is 
hence controversially discussed. Many confounding factors contribute to the complexity 
of the question.  
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First, although nearly identical, the recombinant vector AAV is not the same as the 
wtAAV. Devoid of the capability to replicate and produce its normal viral capsid proteins, 
both of which are triggers of anti-viral immune responses, it is very likely that the immune 
response against rAAV has its own characteristics which can not be deducted from the 
immune response against wtAAV.  
Secondly, as mentioned above, our immune system is able to react differently depending 
on the place of administration of the viral vector. Some organs like the eye are 
immunologically privileged, making the comparison between studies for different target 
diseases and different application routes difficult.  
Finally, pre-clinical safety studies revealed that animal models do not perfectly predict 
the immune response to AAV in humans81. A possible explanation is the difference 
between the immune systems of rodents, larger animals or even NHP and humans. For 
example, the expansion of capsid specific T cells in humans treated with AAV for 
hemophilia B was unexpected, as it had not been observed in the pre-clinical cynomolgus 
monkey model81. This was later attributed to the difference in T cell activation. The T 
cells of humans are known to be more proliferative after activation due to the loss of 
inhibitory surface protein (SIGLEC) expression in human evolution82. 
Besides the immunogenic potential of the viral proteins, an additional question of rAAV 
immunogenicity is the role of the transgene. Principally, potential immunogenic parts of 
the AAV vector not only include the capsid epitopes but also the transgene product. 
Especially in cases of null-mutated patients, one could expect that the transgene product 
would be immunogenic to the host immune system. In the animal model this was shown 
in the case of F.IX gene replacement therapy for Hemophilia B. Cao et al. showed that 
the strength of the immune response correlated inversely with the degree of conservation 
of the endogenous F.IX coding information and thus null mutations leading to the 
strongest immune responses83.  
Luckily for the F.IX therapy development, it was also shown that hepatic gene transfer 
resulted in immunological tolerance induction which limited the transgene-directed 
immune response via Treg cells. In the eye, transgene immunity has not been reported 
making it unclear whether similar tolerance mechanisms to the transgene could play a 
role in ocular gene therapy. 
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Secondly, it is difficult to draw conclusive answers about transgene immunity from 
preclinical animal models as even in target genes which high homology, the actual 
antigenic potential of the respective protein product is usually not known. In humans, 
transgene immunity was neither observed against RPE65 in the initial LCA trials nor 
against F.IX in the hemophilia B trials84, 85.  
In order to monitor the immune response against rAAV, preclinical and clinical safety 
and efficacy studies for different target diseases have most often used the following 
assays84: 
1. The humoral immune response has been assed using a Capsid protein ELISA to 
identify seroconversion and quantity capsid-specific antibodies. Additionally, the 
Goldmann-Witmer coefficient has been used to detect site-specific antibody 
production. 
2. In vitro transduction assays in the presence of a test serum, called neutralizing 
antibody assays, have been used to functionally monitor the ability of antibodies in 
the test serum to inhibit successful transduction. 
3. Cell-mediated immunity has been examined by enzyme linked immunosorbent spot 
(ELISPOT). This assay uses the secreted cytokines like INF-g as a marker of 
activation upon antigen exposure. 
4. Flow cytometry has been used as a way of quantifying the type and level of activation 
of immune cells via CD69 expression following exposure to antigen such as AAV 
capsid proteins. 
5. Morphological changes of the tissue and infiltrating immune cells have been 
visualized in animals by histological methods. 
 
2.7.1 Immune response to rAAV in the eye 
 
For the eye, the results of the RPE65 trials for LCA provided the first patient data of 
immune responses to AAV. The results between the different groups varied a little which 
might be a reflection of the differences in vector and dose. 
The group at the University College London (UCL, Bainbridge et al.) reported that 
intraocular inflammation and immune responses had been observed in 5 out of 8 patients 
of the high dose group (1x10^12 viral genomes), but in none of the 4 patients of the low 
dose group (1x10^11 vg) within three years of follow up after gene therapy with rAAV2. 
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Findings included posterior and anterior intraocular inflammation in three patients, one 
showing also elevated neutralizing antibodies and increased circulating T-cells reactive 
to the AAV2 capsid. No one presented antibodies reactive against the RPE65 protein. 
Except for one patient, where anterior uveitis was followed by macular pigmentary 
changes and persistent reduction in visual acuity, inflammation appeared none deleterious 
and responsive to glucocorticoid treatment.1 
The group at University of Florida (Hauswirth et al.) reported that all eyes (n=6) 
recovered completely under steroid treatment and that the only adverse events were 
related to surgery. Neutralizing antibodies were observed in only two cases but 
interpreted as coincidence since other patients also showed similar titer elevations at 
timepoints where the contact with wtAAV would have been the more likely cause. T-cell 
responses to the AAV capsid were not observed.21 
The group at the University of Pennsylvania (UPenn, Maguire et al.), which has published 
a phase III clinical trial including 20 patients, also did not report any serious adverse 
events related to the test item. Only 2 patients showed signs of intraocular inflammation 
which completely resolved under steroid treatment30. INF-g ELLISPOT assays did not 
detect capsid directed T-cell responses22. The group has also been able to show that the 
re-administration of the same vector to the contralateral eye is safe and efficacious86, 87. 
Even high neutralizing antibodies at baseline had no negative effect on the efficacy of 
administration to the second eye87. Further on, this group investigated T-cell immunity 
against the RPE65 transgene product, which was found to be negative.22, 31 
One can conclude different important facts from these trials. Immune responses were 
generally benign and resolved under steroid treatment. The fact that treatment of the 
second eye is so successful suggests that no relevant adaptive immune response is formed. 
On the other side, the need for immunosuppressive treatment was evident. Ocular 
inflammation was observed in multiple cases and the loss of efficacy over time might be 
explained (in part) by immune-mediated clearing of transduced cells over time. In 
summary, the role of the immune response in ocular gene therapy remained somewhat 
unclear although the extent of its magnitude seemed limited in comparison to the immune 
response against AAV after systemic application.  
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2.7.2 Immune response to rAAV after systemic application 
 
A lot of what is known about rAAV immunity, especially cell-mediated immune 
responses, comes from trials where rAAV is delivered systemically (e.g. intravenously in 
order to transduce hepatocytes). In these trials, systemic application of rAAV elicited a 
systemic und local  (target cell population) cellular immune response, which significantly 
limited the efficacy of the therapy. 
The limitations imposed by cell-mediated immunity were first described by Manno et 
al88. They observed that the transgene expression diminished and liver enzymes rose 
approximately 4 weeks after systemic delivery of rAAV2 (expressing human factor IX). 
At the same time, capsid-specific T cells expanded88, 89. A similar study found the same 
results using an AAV8 vector and described that corticoid treatment was the most 
efficient strategy to prevent loss of transduced hepatocytes9.  
Subsequently, Pien et al. showed that capsid epitopes were presented on the cell surface 
via MHC-I class molecules, making the hepatocytes (or potentially any other transduced 
target cells) susceptible for clearance by CD8 positive T cells81. It was recently shown 
that this antigen presentation is also generated from empty capsids90. 
Some of the receptor pathways that connect the innate immune response against AAV 
with the adaptive immune response have been identified in animal models. The first one 
to be identified was the TLR 9-Myd88 pathway91. TLR 9 is an endosomal receptor that 
senses unmethylated CpG islands within the vector genome92. Confirming these findings, 
experimental transgene depletion of unmethylated CpG islands reduced CD8+ T cell 
responses93.  Myd88 in turn initiates a signaling cascade, that ultimately leads to the 
activation of NF-kB and IL-6, both pro-inflammatory cytokines94. Secondly, it was 
shown that in response to AAV the TLR9-Myd88 pathway led to the release of type I 
INFs in peripheral dendritical cells (pDC)91. Self-complementary AAVs (scAAV) 
showed even higher immunogenicity via TLR 9 compared to single stranded AAV95. As 
mentioned earlier, type I INFs are important signaling molecules responsible for 
orchestrating an antiviral immune response and enhance via MHCI presentation the 
clearance of infected cells through CD8+ T -cells. Interestingly, the proteasome inhibitor 
bortezomib was shown to decrease AAV capsid antigen presentation and by inhibiting T-
cell mediated clearance of transduced cells at the same time enhanced gene expression96. 
B cell intrinsic Myd88 signaling was also shown to be involved in the induction of INF-
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g producing CD4 T cells and the subsequent formation of Th1-associated IgG2 antibody 
responses to AAV97, 98. 
In non-parenchymal liver cells, the capsid of rAAV2 and rAAV8 was shown to be sensed 
by cell membrane-bound TLR299. This is interesting, as for the eye TLR2 – TLR2ligand 
interactions of retinal APCs have been identified to play a role in the activation of 
uveitogenic T cells100. In the retina, not only the resident APCs present TLRs101, 102. 
Photoreceptor cells are also capable of expressing TLRs103, 104. 
Other intracellular receptors which have not yet been linked to AAV recognition but are 
known sensors of viral DNA, include the NOD-like receptors NLRP3 and AIM2. Both 
are known to interact with ASC and Procaspase 1 to form a complex called 
inflammasome, which in turn cleaves  pro-inflammatory interleukines (pro-IL 1b and 
pro-IL18) into their active form in response to cytosolic DNA105, 106. Other receptors that 
might be involved in AAV innate immune response are cytosolic DNA sensors upstream 
of STING (stimulator of interferon genes), like DAI, IFI16, cGAS and DDX41107. The 
activation of STING leads into the Type I INF signaling and has been described to play 
a role in innate immune sensing of other DNA viruses like Herpes virus108. One study 
investigated whether AAV capsid directed CD8 T cell formation was dependent on 
STING signaling but found only the TLR9-Myd pathway uniquely capable of initiating 
this response109. 
 
In a nutshell, although generally considered as non-pathogenic, rAAV is sensed by the 
innate immune system as a foreign particle and can be presented to the adaptive immune 
system. NABs are able to inhibit successful transduction after systemic application of 
AAV, but the eye seems to be immunologically privileged concerning this issue. Cell 
mediated clearance of transduced cells plays a role after systemic application but has not 
been observed after application of AAV to the retina. 
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3 Results 
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PURPOSE. To study longitudinal changes of anti-drug antibody (ADA) titers to recombinant
adeno-associated virus serotype 8 (rAAV8) capsid epitopes in nonhuman primates (NHP) and
patients.
METHODS. Three groups of six NHP each received subretinal injections (high dose: 1 3 1012
vector genomes [vg], low dose: 1 3 1011 vg, or vehicle only). Four additional animals
received intravitreal injections of the high dose (1 3 1012 vg). Three patients received 1 3
1010 vg as subretinal injections. ELISA quantified ADA levels at baseline and 1, 2, 3, 7, 28, and
90 days after surgery in NHP and at baseline and 1, 3, and 6 months after surgery in patients.
RESULTS. Two out of 22 animals lacked ADA titers at baseline and developed low ADA titers
toward the end of the study. Titers in the low-dose group stayed constant, while two of six
animals from the high-dose group developed titers that rose beyond the range of the assay. All
animals from the intravitreal control group showed a rise in ADA titer by day 7 that peaked at
day 28. Preliminary data from the clinical trial (NCT02610582) show no humoral immune
response in patients following subretinal delivery of 1 3 1010 vg.
CONCLUSIONS. No significant induction of ADA occurred in NHP when mimicking the clinical
scenario of subretinal delivery with a clinical-grade rAAV8 and concomitant immunosuppres-
sion. Likewise, clinical data showed no humoral immune response in patients. In contrast,
intravitreal delivery was associated with a substantial humoral immune response. Subretinal
delivery might be superior to an intravitreal application regarding immunologic aspects.
Keywords: gene therapy, vitreoretinal surgery, retina, AAV, immune response, antibodies
Adeno-associated virus (AAV)-mediated gene therapies havebeen shown to be clinically safe and offer new possibilities
for the treatment of genetic diseases, such as blinding retinal
dystrophies. However, investigators have independently found
evidence of immune reactions against AAV vectors, the
transgene, or the transgene product.1–4 These include the full
range of active defense mechanisms including innate, humoral,
and cellular immunity. As such, clinical trials in hemophilia
patients have shown that circulating antibodies can effectively
inhibit transduction even at low titers, and that AAV-directed
CD8! cells target and remove successfully transduced hepato-
cytes as virus-infected cells.5
In contrast to the treatment for hemophilia, where AAV
vectors are injected intravenously, relatively small doses are
administered in the immune-privileged space of the eye for
retinal disorders like Leber’s congenital amaurosis, choroidere-
mia, or achromatopsia. In 2008, different groups independently
reported a modest beneficial treatment effect of AAV2 for the
RPE65 mutation in LCA patients.6–8 In none of these trials were
major adverse advents reported in the following 5 years.
Clinically no inflammation unresponsive to steroids was
observed, and only two patients developed a transient antibody
reaction.9 One study reported a single case in which anti-capsid
antibodies emerged in a functional assay around day 14 but
declined later,6 and in another study some anti-capsid antibody
titers increased toward day 90 but were still low compared to
the overall mean.8 Amado et al.10 showed that subretinal
readministration of an AAV2 vector elicits a humoral immune
response against the viral capsid in large animals. However,
transduction was still possible under these conditions. This is in
line with the observation that readministration of subretinal
AAV (to the contralateral eye) in three adult patients did not
lead to a rise in antibody titer.11 Importantly, though,
intravitreal delivery of AAV2 has been shown to induce humoral
immune response in mice and block transduction in subse-
quent subretinal or intravitreal injections.12 Others have shown
that intravitreal delivery of AAV in NHP results in an increase of
anti-AAV antibodies and decreased transgene expression.13
Although a rise in antibody titer does not seem to be necessarily
harmful, safety of the patient is of paramount importance and
Copyright 2018 The Authors
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the role of a potential humoral immune response should be
fully understood.
To further explore this we injected 22 NHP with different
doses of recombinant adeno-associated virus serotype 8
(rAAV8) as part of a formal toxicology and biodistribution
assessment toward regulatory approval of a phase I/II clinical
trial (NCT02610582). Subretinal or intravitreal administration
routes were used in a surgical setting identical to that in human
subjects (including perioperative steroids). We aimed to
elucidate whether a good manufacturing practice (GMP)-grade
AAV8 vector would lead to a humoral immune response in a
clinical scenario and whether route of delivery would make a
difference. Additionally, the same assay was used subsequently
to quantify anti-drug antibody (ADA) titers in human patients
following subretinal gene therapy (NCT02610582) with the
same vector.
METHODS
Animals and Study Design
A total of 22 NHP (Macaca fascicularis) were allocated into
four separate groups (Supplementary Table 1). Groups 1 to 3
consisted of six animals (three males/three females). Group 1
was treated with vehicle (balanced salt solution [BSS]; Alcon,
Freiburg im Breisgau, Germany) with 0.001% PF-68 (BASF,
Ludwigshafen am Rhein, Germany). Animals in groups 2 and 3
received the test item (rAAV8) in the left eye only via single
subretinal injection. Four animals (two males/two females)
were allocated to group 4 and received the same test item via
intravitreal injection. Animals in group 2 were treated with
low-dose (1 3 1011 vector genomes [vg]) and animals in groups
3 and 4 were treated with high dose (1 3 1012 vg). Animals
used in these studies were cared for and handled according to
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research and after approval by the local authorities
(Regierungspraesidium) and in full compliance with the
guidelines of the European Community (EUVD 86/609/EEC)
for the care and use of laboratory animals, as well as in
accordance with good laboratory practice (GLP) standards as
defined by German GLP monitoring authorities and in
compliance with U.S. Food and Drug Administration GLP
regulations.
Vector and Vehicle
The AAV8 vector was produced according to GMP guidelines
by cotransfection of human embryonic kidney cells followed
by purification and concentration steps optimized for clinical
use of vector solution as reported previously.14
Surgery and Perisurgical Care of NHP
Animals received general isoflurane (Forane; Baxter GmbH,
Unterschleißheim, Germany) and local 2% oxybuprocain
(Conjuncain; Bausch&Lomb GmbH, Berlin, Germany) anesthe-
sia before preparing (peri-)orbital skin with 10% povidine
iodine solution and rinsing the conjunctival fornices with 1%
povidine iodine solution. Sterile surgical drapes and pediatric
lid specula were applied before a temporal canthotomy was
performed for improved access. Three 23-guage (G) trans-
conjunctival sclerotomies were made approximately 1.5 mm
posterior to the limbus and vitrectomy was performed as
completely as possible without affecting the lens. A localized
retinal detachment was induced through subretinal injection of
BSS (Alcon) using a 41-G cannula (DORC 1270.EXT; D.O.R.C.
Deutschland GmbH, Düsseldorf, Germany). Virus solution was
injected into the preformed bleb using a foot pedal–controlled
injection system (PentaSys II; Ruck GmbH, Eschweiler,
Germany). Before recovery, subconjunctival cefuroxime (125
mg; ratiopharm GmbH, Ulm, Germany) and dexamethasone (2
mg, ratiopharm GmbH) were administered to the operated eye.
Postoperative prophylactic treatment consisted of antibiotic
(0.5% Moxifloxacine; Pharm-Allergan GmbH, Frankfurt am
Main, Germany) and anti-inflammatory (1% Prednisolone;
Pharm-Allergan GmbH) eye drops given three times a day
each in the treated eye for 2 weeks and prednisone (Merck
Pharma GmbH, Darmstadt, Germany) 1 mg/kg intramuscularly
from day!2 until day 5. In the course of the study all animals
received ophthalmoscopic screening (slit lamp, fundus biomi-
croscopy) for signs of inflammation at days 2, 3, 7, 22, 50, and
87.
Enzyme-Linked Immunosorbent Assay (ELISA)
Plasma samples were collected from each animal prior to
dosing and at days 1, 2, 3, 7, 28, and 90 post dosing. A total of
154 samples were analyzed using a sandwich ELISA strategy
utilizing a ELISA kit for the determination of AAV serotype 8
particles in cell culture supernatants or purified preparations
(PROGEN Biotechnik GmbH, Heidelberg, Germany; Art. No.:
PRAAV8). The microtiter strips, coated with a monoclonal
antibody specific for a conformational epitope on assembled
AAV8 capsids, were incubated with GMP-grade rAAV8. This
procedure completed the coating for the detection of the new
analyte: anti-AAV8 antibodies. Captured anti-AAV8 antibodies in
plasma samples were detected using an enzyme conjugate of a
rabbit anti-NHP antibody (rabbit anti human [and NHP] IgG
pAb Streptavidin Peroxidase Conjugate, Cat. No. 55221; MP
Biomedicals, Santa Ana, CA, USA). An anti-AAV8 biotin-
conjugated antibody, together with streptavidin peroxidase,
served as positive control. This antibody was used in a serial
dilution of 1:3 from 250 ng/mL down to 0.34 ng/mL. The
highest concentration of 250 ng/mL showed a hook effect and
was therefore regarded as out of the range of the assay. The
remaining seven standard dilutions covered the complete
range, returned from the plasma samples. Eight negative
controls were included on every ELISA plate. For the negative
controls, no plasma was added and the background was
calculated from the mean absorbance of these blanks. The
background mean was subtracted from the plasma samples.
After addition of substrate solution the color reaction was
measured photometrically at k " 450 nm. In order to avoid
false-negative results due to very high concentrations of the
analyte, the plasma samples were measured in serial dilutions
(1:5, 1:25, 1:125).
To ensure the assay’s validity, coating controls, a dilution
sequence of positive controls, and a negative control with no
analyte were included on every ELISA plate. The optimal
assay setting was tested beforehand in a GLP confirming
proof of principle study. The following criteria were
implemented to ensure validity. Uncoated wells had to show
a low absorbance value (ODSTD0 # 0.2). Coating controls (1 3
109, 1 3 108, 1 3 107 vg/mL, no coating) had to show a dose
dependency in mean absorbance values. Coated wells
without analyte had to show a low absorbance value and
give a good signal-to-noise ratio when using a short time for
color reaction and using a blocking solution (ODno Plasma #
0.3). The mean absorbance value of the positive control wells
coated with 1 3 1010 vg/mL (standard 1, STD1) had to be ‡
1.0. The mean absorbance value of the positive controls
(standards 1–8) had to show a dose dependency (STD1 >
STD2 > STD3 > STD4 > STD5 > STD6 > STD7 > STD8).
Plasma from seroconverted animals had to show a clear dose–
dilution relationship.
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As these criteria were all met, the assay was considered to
be appropriate for the detection of anti-AAV8 antibodies.
Analysis
For the NHP samples, the titer was defined as the reciprocal
dilution of the plasma at which the linear, interpolated graph
for individual plasma intersects a so-called titer intercept line
(TIL). The range where the interpolated graph could intersect
the TIL was defined between 5 and 160. In this assay, the TIL
was defined as the 3.3-fold lower limit of quantification (LLOQ)
of the assay. Limit of detection (LOD) and LLOQ were
calculated according to German Institute for Standardization
(DIN) 32654, using the standard deviation (r(x0)) of negative
controls by the following approximation: LOD: 3 3 r(x0);
LLOQ: k 3 3 3 r(x0) (with k! 3 at relative confidence interval
[CIrel] ! 33%). In the case of clinical samples, absolute
absorbance values are reported of all dilutions tested and
compared in a longitudinal fashion.
Some samples did not yield quantifiable results. In these,
titers exceeded or stayed below the dilution range of 1:5 to
1:160. Because we calculated the titer using the slope between
different concentrations, in cases where the absorbance values
did not drop in line with the dilution series (see validation
criteria), the intersection with the TIL was outside the dilution
range (i.e., the reading did not meet the prespecified criteria of
validity). The most likely reason for this is the oversaturation of
the assay due to high titer concentrations or a technical error.
Likewise, plasma samples where all dilutions gave absorbance
values below the TIL were considered below the range.
Patients
Three patients (two male, one female) underwent the
procedure after written informed consent was given and
followed up according to the approved trial protocol
(NCT02610582). The vector was applied via subretinal
injection as described previously.14 All three patients received
1 3 1010 vg of the clinical-grade vector rAAV8.hCNGA3. To
monitor safety, clinical and ophthalmologic examinations were
performed at screening, directly after surgery, and 1, 2, 3 6 1,
14 6 3, 30 6 5, 90 6 7, and 180 6 7 days after surgery. Blood
samples were taken in all patients at screening, as well as 30 6
5, 90 6 7, and 180 6 7 days after surgery. The study was
carried out in accordance with the ethical principles of the
Declaration of Helsinki.
RESULTS
Nonhuman Primates (NHP)
For 141 of 154 NHP samples, a titer for rAAV-specific
antibodies could be calculated, while 13 samples (8%) were
out of the range of the assay. Of these, eight were above the
range of the assay (titer > 160), and five samples showed no
seroconversion (titer < 5). In total, 20 of 22 animals were
already seroconverted before application. The two seronega-
tive animals (28011M, 28017M), both allocated to the low-dose
group, developed very low antibody titers throughout the
observation period (maximum titer: 19, 28011M, day 28). No
sex-specific differences in the rAAV8 specific antibody titers
were observed.
In the vehicle control group (Fig. 1A), the change of titer
(day x " day 1) ranged from "28 in animal 28023M to #50 in
animal 28062F. This represents the test variability and
individual titer fluctuations, which occur without an ongoing
inflammatory reaction since none of the animals received
vector. In the low-dose group (Fig. 1B) we observed titer
changes similar to the control group with a titer change range
from"30 to#36. As such, the antibody titers of the subretinal
low-dose group stayed constant over the entire observation
period. Although no statistical analysis is applicable, no titer
changes obviously different from those of the vehicle control
group were observed. Interindividual differences as well as the
time curve for the titers found in the low-dose group are similar
to those of the vehicle control group. In the high-dose group
(Fig. 1C), two animals had titers that were above the range of
the ELISA assay (animal 28060F day 28, animal 28063F day 7
and day 28). Where titers exceeded the range of the assay
(160), no titer change was calculated. With the three missing
values put aside, the titer change in group 3 ranged from "25
to #68. The relevance of the missing values will be discussed
later. In the intravitreal control group (Fig. 1D), which received
the same dose as the high-dose group, the mean titer change
was most pronounced compared to all other groups. All
animals showed a tendency toward higher titers 7 to 28 days
after surgery. In three out of four animals, titers began to rise
by day 7, peaked at day 28, and declined toward day 90 but
remained elevated above baseline. The titer change on day 7
ranged from#34 to#98 and on day 28 from#38 to#140. The
maximum titer change was #140 (animal 28057F day 28).
Individual titers for each animal and time point are shown in
Supplementary Figures S1 through S4.
Patient Samples
We tested plasma samples from the first three patients with
CNGA3-linked achromatopsia undergoing gene therapy
(NCT02610582), which applies the same vector construct
used in the NHP study above. The same ADA test was applied
and showed no humoral immune response within the first 6
months following subretinal delivery of 1 3 1010 vg (Fig. 2). All
three patients had quantifiable absorbance measurements at
baseline, which did not change significantly at 1, 3, or 6
months after subretinal vector delivery.
DISCUSSION
Through contact with wild-type AAV, humans develop anti-
bodies against the different serotypes in their first years of
life.15,16 Depending on the study, seroprevalence for AAV8
ranges from 15% to 30% of the population (AAV2: 30%–
60%)16,17 to 82% in Asian adult humans (AAV2: 97%).18
Seroprevalence for AAV8 in NHP is considered to be as high
as in humans or even higher.19 Accordingly, in our study, 20 of
22 animals were found to be seropositive for anti-rAAV8
antibodies, indicating a seroconversion before the first
treatment. Likewise, all patients from the first cohort (n ! 3)
of the clinical trial (NCT02610582) had quantifiable absor-
bance values in the ADA assay at baseline.
In general, after infection with a virus, the immune system
requires a few days to develop a specific humoral immune
response. Although it is difficult to exactly predict the
temporal dynamics of a humoral immune response against
AAV epitopes, antibody titers in a clinical gene therapy trial for
hemophilia using rAAV8 rose after 1 to 2 weeks.5 Antibody
titers rising in a similar time frame after rAAV8 delivery can
therefore be attributed to a specific humoral immune response.
This is what we observed in our intravitreal control group
where antibody titers began to climb on day 7 and peaked at
day 28 (no samples were taken in between, e.g., on day 14).
Hence, a specific humoral immune response in NHP after
intravitreal delivery of rAAV8 serves as a parsimonious
explanation.
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Although no evidence is at hand for the missing values of
the two animals of the high-dose group, 28060F and 28063F,
having the previous considerations in mind, one could
interpret these titers above the range of the assay on day 28
(28060F) and days 7 and 28 (28063F) as a humoral immune
response. In both animals, titers declined toward an elevated
level above baseline on day 90, which is consistent with what
we observed in the intravitreal control group. Apart from these
two animals, all other rAAV antibody titers in the high-dose
group, as well as all rAAV antibody titers of the low-dose group,
stayed constant over the 90-day observation period.
Since ELISA values for antibodies against AAV serotypes are
not comparable between different studies it is difficult to make
a decision on what titer change is considered a relevant
change—especially since high titers do not translate into
clinical findings. In our study we used the variability of control
group data to assess which change in titer was numerically
significant. It is important to remember, however, that this
does not equate to clinical significance. Indeed, we observed
no clinically relevant, test item–related changes in ophthalmo-
logic assessment throughout the in-life phase of the study.
Findings observed (limited and temporary anterior chamber
flare and cells, drusen, and pigment clumping) were either also
present before dose and thus regarded as background lesions
(e.g., drusen), or equally evident in groups 1 to 3 and therefore
related to the surgical procedure rather than the test item. The
fact that none of the 22 primates presented signs of a clinically
relevant inflammation shows that a rise in antibody titer cannot
be directly correlated to a clinically significant pathogenic
process. It may, however, become relevant in a scenario of
multiple injections and/or intravitreal applications.3,18 Intravit-
real may be considered the preferred route of administration
when targeting inner layers or wide areas of the retina.20
However, some authors have suggested that after intravitreal
injections, neutralizing antibodies are more likely to be
generated than after subretinal injections and that these
antibodies have the potential to inhibit effective gene
transfer.12,13 Part of the explanation for this enhanced humoral
immune response might be the fact that the shedding and
biodistribution of vector after intravitreal injections is consid-
erably higher.21
This study has certain limitations, including absence of
absolute thresholds of clinical relevance for levels of antibodies
against AAV8. Furthermore, there is no international standard
FIGURE 1. Individual titer change in individual animals presented as D to baseline (day 1). (A) Control group, (B) low-dose group (1 3 1011 vg), (C)
high-dose group (1 3 1012), (D) intravitreal high-dose group (1 3 1012). Titers are calculated as described in Methods. Where titers exceeded the
range of the assay (upper range of titer calculation: 1:160), no titer and no titer change could be calculated ([C] 28060F day 7 and 28063F days 7 and
28; [A] 28010M at all time points and therefore not included in graph).
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for benchmarking across studies. As such, dilution series and
longitudinal follow-up are important aspects in these investi-
gations. Another limitation is the lack of true technical repeats
in the ELISA. Instead, each sample was measured in a dilution
sequence and the titer calculated by using the slope instead of
single values. This has the added benefit of accounting for
differences in antibody affinity as a function of epitope
concentration.
One needs to be cautious when extrapolating results
from studies in NHP to the clinical situation because the
response of the immune system of NHP to the therapeutic
vector may differ from that of human subjects. However, we
believe that our findings may help guide study designs of
future clinical gene therapy trials. We argue that this assay
can specifically detect antibodies against AAV8 epitopes and
is appropriate for the comparison of pre- and postdose
plasma specimens. Since our results rely on rAAV8, we can
only speculate about the effects of other serotypes. It seems
possible, though, that the time course of the humoral
immune response as well as the effects of different routes of
administration may be similar for the commonly used vector
AAV2 and other serotypes.
In conclusion, our results show an excellent safety profile,
especially regarding the low dose (1 3 1011 vg). This is
important, as this dose was chosen as the highest dose used
for the c l in ical t r i a l in achromatops ia pat ients
(NCT02610582). Groups 3 and 4, having received 1 3 1012
vg, showed more equivocal results, with some samples
exceeding the range of the ADA assay. In general, the route
of administration seems to have dictated the humoral immune
response against AAV8: While an intravitreal approach
promises the potential of panretinal transduction without
the challenges of subretinal surgery, this study adds evidence
to the observation that intravitreal injections are associated
with a higher risk for humoral immune responses compared
to subretinal delivery of AAV vectors. An ongoing trial with
intravitreal application of AAV8 for X-linked juvenile retinos-
chisis (NCT02416622) will help to further clarify this
observation.
More research is needed to understand the complex
reaction to AAV in the immune-privileged eye. The ocular
immune response against AAV beginning with innate mecha-
nisms and leading to specific humoral/cellular immunity is still
poorly understood. It is of eminent importance to gain a good
knowledge of the mechanisms underlying the antiviral defense
mechanisms of the visual system. This will allow further
improvement of safety and enhancement of efficacy of AAV-
mediated gene therapies in the eye.
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1University Eye Hospital, Centre for Ophthalmology, University Hospital Tübingen, Tübingen, Germany; 2Institute for Ophthalmic Research, Centre for Ophthalmology,
University Hospital Tübingen, Tübingen, Germany; 3Immunopathology Laboratory, Department of Internal Medicine II, University Hospital Tübingen, Tübingen,
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Ocular gene therapy has evolved rapidly into the clinical realm
due to promising pre-clinical proof-of-concept studies, recog-
nition of the high unmet medical need of blinding disorders,
and the excellent safety pro!le of the most commonly used vec-
tor system, the adeno-associated virus (AAV). With several
trials exposing subjects to AAV, investigators independently
report about cases with clinically evident in"ammation in
treated eyes despite the concept of ocular immune privilege.
Here, we provide a detailed analysis of innate and adaptive
immune response to clinical-grade AAV8 in non-human pri-
mates and compare this to preliminary clinical data from a
retinal gene therapy trial for CNGA3-based achromatopsia
(ClinicalTrials.gov: 02610582).
INTRODUCTION
Only one decade has lapsed since the !rst ocular gene therapy in
humans.1–3 Since then, the !eld has evolved rapidly for three reasons.
First, blinding disorders demonstrate high unmet medical need with
no treatment available. Second, pre-clinical proof-of-concept studies
using adeno-associated virus (AAV) showed convincing ef!cacy in
the absence of signi!cant toxicity. Third, the eye is regarded as an
attractive target organ due to the availability of an internal control
(fellow eye), its small size, and its diagnostic and therapeutic accessi-
bility and not least due to the concept of ocular immune privilege
initially described by Medawar4 70 years ago.
The initial reports from clinical trials con!rmed the excellent safety
pro!le of AAV and showed some evidence of ef!cacy. However, the
endpoints used were psychophysical measures such as global light
sensitivity and mobility tests in an open-label trial. Objective mea-
sures of ef!cacy such as electroretinography (ERG) were not able
to reproduce the results gained from pre-clinical studies in dogs.
The long-term data on the !rst two independently led retinal
gene therapy trials suggested a decline of therapeutic ef!cacy with
time.5,6 Different hypotheses have been brought forward to explain
this decline of visual function, including silencing of the episomal
transgene, continuous degeneration despite transduction of cells
past the point of no return, and clearance of transduced cells by im-
mune mechanisms.
Immune-mediated clearance of cells transduced with AAV has been
observed in clinical trials targeting hepatocytes, which are not im-
mune privileged and are in plain sight of the immune system.7 In
contrast, the eye features passive and active mechanisms to counteract
in"ammation, such as the blood-retina barrier; lack of anatomically
de!ned lymphatic drainage; abundance of local anti-in"ammatory
agents (e.g., transforming growth factor b [TGF-b], a-melanocyte
stimulating hormone [a-MSH], and somatostatin [SOM]); and
monocytes actively counter-acting adaptive immunity (e.g., F4/80+
antigen-presenting cells [APCs] and CD8+ Treg cells).
8 It hence
came as somewhat of a surprise that Bainbridge et al.1,6 reported
some degree of intraocular immune responses in !ve of eight high-
dose patients following subretinal treatment with AAV2, of which
one showed a persistent reduction of visual acuity following a mild
anterior uveitis. Independently, MacDonald et al. (2016, Invest.
Ophthalmol. Vis. Sci., abstract) presented a case of clinically evident
intraocular in"ammation after subretinal gene therapy. Following the
application of serotype 2 AAV, intraretinal hyper-re"ective spots
appeared in optical coherence tomography (OCT) scans of the treated
retina reminiscent of cellular in!ltration by glia or other immune-
competent cells. These changes dissolved after a course of systemic
steroid treatment, adding to the notion that immune-competent cells
played a role.
Here we report data suggesting activity of both innate and adaptive
immunity in eyes of non-human primates (NHPs) that had received
subretinal injections of clinical-grade AAV8 under concomitant
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steroid treatment. Furthermore, we set this in context with prelimi-
nary clinical data from the !rst retinal gene therapy trial for
CNGA3-based achromatopsia (ClinicalTrials.gov: 02610582).
RESULTS
Successful Delivery of Clinical-Grade AAV8 in 34 Cynomolgus
Monkeys
All animals successfully received intraocular surgery mimicking clin-
ical application, including concomitant systemic and local steroid
treatment, transconjunctival 23G pars plana vitrectomy, and either
intravitreal or subretinal injection of a prede!ned dose of clinical-
grade AAV8 in vehicle (buffered saline solution [BSS] with 0.001%
Kolliphor P188 Micro surfactant) or vehicle only. The study design,
speci!cs of dosing, and sex distribution are summarized in Table 1.
First, a 90-day study was conducted in 22 animals randomized into
groups receiving either subretinal vehicle (group 1), subretinal low
dose (1 ! 1011 vector genomes [vg]; group 2), subretinal high dose
(1! 1012 vg; group 3), or intravitreal high dose (1! 1012 vg; group 4).
The rationale for including an intravitreal control group was to assess
the biodistribution and toxicity following an inadvertent injection
into the vitreous cavity and/or major re"ux through the retinotomy
secondary to a subretinal delivery. Dosing was performed without
complication except lens touch in two animals, which subsequently
developed lens opaci!cations. The pars plana was consistently found
2 mm posterior of the limbus. Introduction of consecutive trocars for
vitrectomy was dif!cult due to the sturdy sclera and required extra
care to avoid hypotonic collapse of the eyeball and inadvertent
damage to ocular tissue such as the posterior lens capsule. The adhe-
sive force between the retinal pigment epithelium (RPE) and the
neuroretina was greater than in human patients, which necessitated
high initial infusion pressures. To overcome the adhesive force
and induce the neurosensory detachment with BSS in a two-step
approach,9 peak pressures reached% 50 mmHg (6.7 kPa) in animals,
compared to maximal infusion pressures of 30 mmHg (4.0 kPa) in
human patients using the same setup (PentaSys II, Ruck). Placement
of the retinotomy just inside the vascular arcades, halfway between
optic disc and fovea centralis consistently led to a central macular
bleb and promised ef!cient targeting of cone photoreceptors. Gravi-
tational forces were insuf!cient to displace the bleb in an inferior
direction.
All blebs had resolved by the !rst ophthalmological follow-up on day
three. Clinical slit lamp and fundus biomicroscopy revealed limited
numbers of white cells in the anterior or posterior chamber across
the groups (Figure 1). In!ltration of the anterior chamber peaked
three days after surgery. White cells in the posterior segment only
became evident after one week or later. Cellular in!ltrations found
in anterior and posterior segments were less severe in the groups
only undergoing the surgery without AAV8 exposure (group 1) or
being exposed to AAV8 but being spared the subretinal injection
(group 4), while subretinal surgery combined with AAV8 exposure
(groups 2 and 3) led to the highest overall scores. Fundoscopy and
imaging of the posterior pole showed only minor changes (Figure 2),
such as the expected pigment displacement !rst reported by Nork
et al.10 Color photographs, infrared, and auto"uorescence recordings
all revealed the pigment displacement re"ecting the area of detach-
ment. Angiography showed that perfusion characteristics remained
unchanged and the blood-retina barrier intact. Retinal thickness
temporarily decreased due to transient loss of photoreceptor outer
segments following retinal detachment and re-attachment. However,
signal composition in the outer retina normalized over time and a
formal non-inferiority analysis on the effect of subretinal versus intra-
vitreal injection on the outer nuclear layer showed that subretinal sur-
gery was not inferior to intravitreal application.11
At 90 days after gene therapy, there were no test item-related changes
in organ weights, in macroscopic or in histopathological observations
of ocular and extraocular tissue. Speci!cally, no degenerative, in"am-
matory, or hyperplastic abnormalities were found in any animal.
Minor changes in the treated eyes consisted of irregularities of the
pigment granules in the RPE, which were attributed to the subretinal
dosing procedure, because they were equally evident in the vehicle
control group.
To further exclude transient effects at an earlier time point, an
additional 28-day study was conducted in 12 animals injected
subretinally at dose levels of 0 (vehicle), 1 ! 1011, and 1 ! 1012 vg
(Table 1). No intravitreal control group was included in the 28-day
study. Based on microscopic observations in retinal sections (Fig-
ure 3), subretinal administration of 1 ! 1012 vg AAV8 resulted in
marked mononuclear cell in!ltration in the retina and choroid in
two animals (both female) evident 28 days after surgery. These
were associated with augmented cellular in!ltrates into the subretinal
space or with marked perivascular to diffuse mononuclear in"amma-
tory cell in!ltrates in the retina and choroid. One male animal from
the subretinal high-dose group also showed a choroidal in"ammatory
cell in!ltrate, but it was ofmuch smaller magnitude. Animals from the
subretinal low-dose group (1 ! 1011 vg) demonstrated only minor
in!ltrates of mononuclear cells, which were also found in subretinal
vehicle-treated animals and thus may constitute incidental back-
ground !ndings. Table 2 summarizes all relevant microscopic
observations.
Table 1. Study Design
Group Dose Level
Route of Delivery
(Volume)
Number of
Animals Sex F/M
90-Day Study (n = 22)
1 vehicle subretinal (200 mL) 6 3/3
2 low, 1 ! 1011 vg subretinal (200 mL) 6 3/3
3 high, 1 ! 1012 vg subretinal (200 mL) 6 3/3
4 high, 1 ! 1012 vg intravitreal (200 mL) 4 2/2
28-Day Study (n = 12)
1 vehicle subretinal (200 mL) 4 2/2
2 low, 1 ! 1011 vg subretinal (200 mL) 4 2/2
3 high, 1 ! 1012 vg subretinal (200 mL) 4 2/2
www.moleculartherapy.org
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Innate Immune Response following Retinal Gene Therapy
Retinal sections from all animals of the 28-day study (speci!cally
including those with evident mononuclear cell in!ltration in the
retina and choroid) were selected for RNA extraction, reverse tran-
scription, and quanti!cation of antiviral response marker expression.
Expression analysis comparing animals with in"ammation evident in
histological assessment (n = 3 from the high-dose group) to animals
of the sham-injected group showed that innate immune response was
activated in those animals and that the innate immune response was
dominated by markers related to the pro-in"ammatory T helper
(Th) 1 pathway (e.g., interferon-gamma [IFNg]-induced CXCL10)
and LGP2, a retinoic acid-inducible gene 1 (RIG-I)-like receptor
responsible for cytosolic viral DNA detection (Figure 4; Table 3).
Humoral Immune Response against AAV8 Capsids
Sandwich-ELISA was used to investigate longitudinal changes of anti-
body titers directed against AAV8 capsid epitopes in the 22 animals of
the 90-day study before and after receiving subretinal injections (high
dose, 1 ! 1012 vg, n = 6; low dose, 1 ! 1011 vg, n = 6; or vehicle only,
Figure 1. Grading Inflammation in the Anterior and
Vitreous Chambers
Animals from all groups underwent slit lamp and fundus
biomicroscopy before surgery (BL, baseline) and at five
time points (3, 7, 22, 50, and 87 days) after surgery to
grade the inflammation in the anterior (left) and posterior
(right) segment of the treated eye following the classifi-
cation of the Standardization of Uveitis Nomenclature
(SUN) working group and the NIH classification.
n = 6) or intravitreal injections (1 ! 1012 vg,
n = 4) mimicking via falsa application. These
data have been published elsewhere (Reichel
et al., 2016, Invest. Ophthalmol. Vis. Sci., ab-
stract). Brie"y, titers of total antibodies (both
neutralizing and binding antibodies) against
AAV8 capsid epitopes remained constant in
all animals of the subretinal dose groups over
the 90-day observation period. Animals from
the intravitreal group showed some response
with elevated titers at 4 weeks post-treatment.
Data on humoral immune response in the
28-day study was not separately available, but
the longitudinal analysis of titers from the
90-day study included time points at 7 and
28 days, which adhered to the general trend
described earlier.
Adaptive Immune Response following
Subretinal Gene Therapy
Cryosections from subretinally treated animals
from the 28-day study featuring mononuclear
cell in!ltrates in the subretinal space and/or
perivascular retina were subjected to immuno-
histochemistry to further de!ne the pro!le of ocular immune activa-
tion following AAV8-mediated retinal gene therapy. Retinal sections
traversing the treatment area demonstrated activity associated with
adaptive immune response (Figure 5). Staining for ionized calcium-
binding adaptor molecule 1 (IBA1), a hematopoietic marker for mi-
croglia and macrophages, showed substantially more signal in eyes,
which had received AAV8. Similarly, CD8+ staining indicated the
presence of cytotoxic T cells in the outer and inner retina of AAV8-
treated eyes. In line with a general immune response, these sections
also showed positive staining for F4/80, human leukocyte antigen-
antigen D related (HLA-DR), and much higher levels of major histo-
compatibility complex class I (MHC I) expression, suggesting active
antigen presentation with the potential for T cell activation. Next to
microglia and macrophages, cytotoxic T cells, and APCs, we also
found CD20+ B cells associated with the in"ammation following
AAV8 application. The presence of cytotoxic T cells and B cells in
the AAV8-injected areas, coupled with microglia and macrophages
and APCs, supports the notion that both innate and adaptive immune
responses play a role in the retina after AAV vector deployment.
Molecular Therapy
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Preliminary Data from Clinical Applications
Clinical application was initiated following unconditional approval by
the relevant regulatory agency (Paul Ehrlich Institute, Germany) and
the ethical review board of the University of Tübingen. This was based
on the observation that there were no test-item-related changes found
in the NHPs 90 days after surgery. The observation of potential, tran-
sient in!ammation at four weeks in NHPs prompted regulators to
de"ne a minimum of 4 weeks between enrollments of trial subjects
and ask for go or no-go decisions from an independent data-moni-
toring committee before each dose escalation. The "rst patient was in-
jected in November 2015, and blood samples were taken one week
before and 3, 14, 30, 90, and 180 days after surgery. C-reactive protein
(CRP), total immunoglobulinM (IgM), and immunoglobulin G (IgG)
did not show clinically signi"cant changes in the "rst cohort of pa-
tients (n = 3, receiving 1 ! 1010 vg), and patients remained clinically
healthy. Stimulation of isolated peripheral blood mononuclear cell
Figure 2. Change in Retinal Structure after
Subretinal Surgery for Retinal Gene Therapy
Pictures from a representative case at baseline (left),
14 days (middle), and 90 days (right) after subretinal in-
jection. Top panels show the color photographs (CP) and
a diagram (middle panel) indicating the bleb size and
location (dotted line) and retinotomy site (cross) in this
animal. The infrared (IR) images show mild changes in
pigment distribution, which are more clearly highlighted in
the autofluorescence (AF) recordings. Fluorescein angi-
ography (FLA), however, shows an intact blood-retina
barrier and no leakage. Optical coherence tomography
(OCT) demonstrate temporary changes in the signal
composition in the outer retina that seem reversible by
day 90.
(PBMC) subfractions from subject 103 with
AAV8 particles at different concentrations (Fig-
ure 6) led to higher activation rates when as-
sessed before compared to after surgery (which
can be partly explained by concomitant steroid
treatment at 1 mg/kg bodyweight from the day
before surgery until day 19). In the other two
subjects, cytotoxic T cells (CD3+/CD8+) showed
the most marked changes in the activation
pattern around 30 days after surgery (despite
the same steroid regimen). These preliminary
clinical data suggest activation of cytotoxic
T cells, supporting the results shown in the
NHPs on activation of cytotoxic T cells in the
AAV-injected areas.
None of these three patients showed clinically
evident cellular in"ltration of the anterior
chamber and/or vitreous cavity at any time.
No patient complained of symptoms or showed
clinical signs associated with in!ammation of
uveal tissues, such as anterior uveitis or panu-
veitis, and visual function reached baseline again two weeks after
surgery. However, one of the patients (subject 102) demonstrated hy-
per-re!ective spots in the virtual cross sections of the treated area with
a peak two weeks after surgery, which resolved under the concomitant
steroid treatment as per protocol (1 mg/kg bodyweight [70 mg] for
three weeks, followed by weekly reduction to daily doses of 50, 40,
30, 25, 20, 15, 10, 5, and 0 mg) without sequelae (Figure 7; Figure S1).
DISCUSSION
Gene therapy offers great hope to patients with hereditary diseases of
the eye and could lead to treatment modalities for more common dis-
eases of the eye (e.g., age-related macular degeneration) and beyond.
However, this potential can only be leveraged if risks and bene"ts are
well understood so that they can be weighed against each other by
regulators, investigators, and patients. The immune system can
play a vital role in gene therapy, and the assumptions that AAV is
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non-immunogenic and the immune privilege of the eye is complete
are not supported by current evidence. Both early and late in!amma-
tory reactions have been described in patients by independent inves-
tigators following AAV2-based ocular gene therapy (MacDonald
et al., 2016, Invest. Ophthalmol. Vis. Sci., abstract).5,6,12,13 Only a
small subset of patients also suffered from functional consequences,
and no life-threatening condition has been reported. However, it
seems sensible to further our understanding of underlying risks
related to immune response and ocular gene therapy in an effort to
maximize safety and ef"cacy of clinical gene therapy.
Vandenberghe et al.14 reported on the transduction pattern and ef"-
ciency of the AAV2 and AAV8 pseudotyped vector in cynomolgus
monkeys and showed a dose-dependent humoral immune response
(increases in neutralizing antibodies to the vector capsid) when using
vector batches produced in the lab under non-guanosine monophos-
phate (GMP) conditions. In animals treated with the highest dose
(1 ! 1011 vg), they demonstrated no T cell activation in response to
vector capsid after injection, while T cell responses to the GFP trans-
gene product in the peripheral organs (such as blood and spleen) were
detected in two of 14 injected animals. The eyes exposed to the same
dose demonstrated focal spots of retinal in!ammation, retinal thin-
ning, and disrupted retinal architecture.14
Maclachlan et al.15 documented an interesting pre-clinical safety and
biodistribution study in the same species using clinical-grade AAV2
as vector containing a synthetic transgene encoding for a modi"ed
soluble Flt1 receptor (sFLT01) designed to neutralize vascular endo-
thelial growth factor. In this study, injection of the maximal dose
(2.4 ! 1010 vg) into the vitreous cavity was associated with an im-
mune response involving lymphocytes or plasma cells in"ltrating
ocular tissue. PBMCs were shown to react to AAV2 capsid protein,
but not to sFLT01.
Although these studies supported the view that AAV has the potential
to stage an adaptive immune response in the eye, they left several
important aspects relevant for the treatment of monogenic disorders
of photoreceptors to be addressed. In contrast to AAV2, whichmainly
transduces ganglion cells after intravitreal application, subretinal de-
livery of AAV8 leads to ef"cient photoreceptor transduction.14 Our
study therefore explored the effects of subretinal AAV8 gene therapy
at a dose range relevant for clinical gene replacement therapy (up to
42 times higher than in the Maclachlan et al.15 study).
Ye et al.16 reported signi"cant chorioretinitis following subretinal
AAV5 supplementation gene therapy in CNGB3 mutant dogs and
dose-dependent ocular in!ammation after subretinal delivery of
either AAV5 or AAV2tYF in healthy cynomolgus monkeys. One
macaque in the lower-vector dose group developed clinical endoph-
thalmitis, and multiple neutrophilic in"ltrates in ocular tissues,
including the retina, were found in an undisclosed number of ani-
mals. NHPs from the high-dose group showed moderate or severe
in!ammation of the anterior and/or posterior eye segments associ-
ated with whitish subretinal foci, which correlated microscopically
with mononuclear cell in"ltrates of the choroid and/or retina.
Ramachandran et al.17 assessed the novel vectors AAV7m8 and
AAV8BP2 expressing GFP after intravitreal or subretinal delivery
in NHPs and showed in!ammatory responses at the highest dose
(1 ! 1012 vg). Speci"cally, they reported some degree of glial activa-
tion and lymphocytic in"ltrates in the retina following application of
1 ! 1012 vg AAV7m8. These "ndings were more pronounced after
subretinal versus intravitreal delivery. In addition, perivascular
in!ammation in the retina, loss of RPE, and chronic choroidal in!am-
mation was observed after subretinal delivery of 1 ! 1012 vg
AAV7m8, but not after intravitreal application of the same dose.
Up to 1 ! 1012 vg AAV8BP2 was applied via either route of delivery
without signi"cant retinal in"ltrates.
Clinical evidence for a dose-dependent in!ammatory response to
ocular gene therapy was "rst reported by Bainbridge et al.6 While
no participant of their low-dose (1 ! 1011 vg) cohort that received
AAV2 encoding RPE65 showed any clinical sign of in!ammation,
"ve of eight participants from the high-dose group (1! 1012 vg) pre-
sented with intraocular in!ammation. Speci"cally, "ndings included
anterior uveitis, focal chorioretinal pigmentary changes, mild vitritis,
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Figure 3. Mononuclear Infiltrates 28 Days after High-Dose Subretinal Gene Therapy with AAV8
(A and B) Representative findings from animals of the high-dose (1 ! 1012 vg) group showing (A) perivascular, intraretinal infiltrates (arrowhead) and (B) choroidal, subretinal
infiltrates (arrowhead). In contrast, retinal architecture is essentially recovered one month after surgery in the vehicle control group (C). Scale bar, 50 mm.
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optic disc swelling, retinal vascular tortuosity, and sheathing of ves-
sels. Apart from the focal pigmentary changes, all !ndings resolved
under steroid treatment, and only one patient showed sustained
reduction of visual function. In a different trial, MacDonald et al.
(2016, Invest. Ophthalmol. Vis. Sci., abstract) showed a case of hy-
per-re"ective spots in the treated area of a choroideremia patient
weeks after subretinal AAV2-mediated gene therapy (1 ! 1011 vg)
that resolved under steroid treatment, bringing the patient back to
his baseline visual acuity.
Although it is clear from these studies that AAV-mediated gene ther-
apy has the potential to trigger an immune response in the eye, a
number of questions highly relevant to the !eld are still to be
answered. These mainly concern the nature of the immune response
(e.g., regulatory versus cytotoxic immune-competent cells and Th1-
versus Th2-dominated response), the causality (e.g., capsid versus
transgene and null versus missense mutations), and the possibility
of modulating the response (e.g., by dose or duration of concomitant
steroid treatment, excluding pre-existing immunity, and method of
delivery).
In a !rst attempt to address immune responses to AAV in the retina,
we analyzed data from good laboratory practice (GLP) conform toxi-
cology studies in 34 cynomolgus monkeys that were subjected to
clinical-grade AAV8 vectors and preliminary data from the !rst clin-
ical trial for CNGA3-based achromatopsia. We were able to show that
surgical delivery of the vector was safe and did not result in a signif-
icant loss of photoreceptors or in other anatomical changes apart
from pigment displacement. However, some animals from the
high-dose group (1 ! 1012 vg) demonstrated mononuclear in!ltrates
in the retina and choroid. In addition, expression pro!ling revealed
upregulation of IFNg-mediated cytokines of the pro-in"ammatory
Th1 pathway four weeks after subretinal injection. Immunohisto-
chemical analysis showed that antigen presentation is augmented in
the treated areas, glial activity is increased, and cells of the adaptive
immune response populate the treated retina. Speci!cally, CD8+
T cells and CD20+ B cells were evident in the retina following appli-
cation of 1 ! 1012 vg AAV8 one month after the surgery. No in"am-
mation was seen histologically in other animals that were sacri!ced
three months after the surgery, opening the possibility of a transient
reaction. One may speculate that active components of the deviant
ocular immune response (e.g., regulatory T cells or APCs, TGF-b,
a-MSH, and SOM) contain such an in"ammatory response. This
raises the question of whether concomitant steroid treatment is bene-
!cial (limiting a harmful immune response) or harmful (incapacitat-
ing the cellular regulatory component of the deviant immune
response), a question worth addressing in future studies.
We observed some degree of discrepancy between the cellular and the
humoral adaptive immune response. There was minimal change of
antibody titers against AAV8 capsid after subretinal delivery, while
the intravitreal group showed an increase in titers (Reichel et al.,
2016, Invest. Ophthalmol. Vis. Sci., abstract). This may re"ect our
previous observations of a more favorable biodistribution pro!le after
subretinal versus intravitreal application of AAV8 (Seitz et al., 2016,
Invest. Ophthalmol. Vis. Sci., abstract). Intravitreal delivery leads to
several orders of magnitude more AAV particles in the systemic cir-
culation and lymphatic tissue compared to subretinal delivery, which
in turn may explain a more robust humoral immune response (Seitz
et al., 2016, Invest. Ophthalmol. Vis. Sci., abstract).
There was no clinically relevant in"ammation of either the anterior or
the posterior segment at any time point in our patients that would not
respond to standard medical care. The previously described patient
with discreet hyper-re"ective spots in the spectral domain OCT
(SD-OCT) virtual cross sections of the treated retina four weeks after
surgery never showed functional loss. The hyper-re"ective dots
resolved under steroid treatment until the next scheduled visit
(month 3) without sequelae. It is unclear what the microscopic equiv-
alent of these hyper-re"ective spots is, but in"ammatory cells or dis-
placed pigment epithelium is likely a candidate.
The study was primarily designed as a GLP conform toxicology and
biodistribution study in preparation of an investigational new drug
(IND) application with the relevant regulatory authority. As such,
limitations of the study include the low number of time points inves-
tigated (28 and 90 days), the !xation of the tissue, and the lack of
PBMC analysis and antigen-speci!c immune response (ASR) assays.
These could have proved or ruled out immune reactivity against hu-
man CNGA3. However, the high homology between the orthologs in
macaques and those in humans (>96%) and the lack of any previous
ASR in the eye of healthy macaques and/or human patients with
Table 2. Microscopical Findings in Subretinally Treated Eyes 28 Days after Gene Therapy
Finding Group 1 (Vehicle) Group 2 (1 ! 1011 vg) Group 3 (1 ! 1012 vg)
Individual animal no. 28364M 28379M 28380F 28383F 28370 28376M 28384F 28390F 28367M 28375M 28381F 28383F
Cellular in!ltrate in the sclera – – – – f – – – – – – –
Cellular in!ltrate in the ciliary body/ora serata – – – – – f – f – – – –
Cellular in!ltrate in the choroid – – – – – – – m – – –
Cellular in!ltrate in the retina – – – – – – – – – – m m
Cellular in!ltrate in the subretinal space – f f f f – – f f – f f
f, focal; m, multifocal.
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either missense or null mutations following gene supplementation
make this rather unlikely.5,6,12,15,16 The primary goal of this study
was to provide GLP conform data on toxicology and biodistribution
in the advent of a clinical trial, and any ASR in animals against a
human antigen would not have been predictive of the risk in a !rst-
in-man trial.
The immune response in NHPs can be different from that observed in
human patients, and the seroprevalence for AAV8 capsid proteins is
higher in NHPs versus the human population.18–20 As such, the im-
plications of the results in the clinical setting have to be substantiated
by further investigations and most importantly by careful observa-
tions in ongoing and future clinical trials. The NHP study supported
our strategy of subretinal delivery in the clinical trial but cautioned us
to monitor our patients carefully in this !rst-in-man study and
prompted the regulatory body to insist on a one month delay between
individual surgeries.
The experimental data presented in this paper suggest the presence of
innate and adaptive immune responses following AAV administra-
tion. The innate immune response seems to activate all three main
pattern recognition pathways (Toll-like, NOD-like, and RIG-I-like
receptor pathways) and initiate a Th1 response. This is supported
by the evidence of microglia activation, the recruitment of cytotoxic
T cells and CD20+ B cells into the retina. The eye was long considered
an immune-privileged organ favoring application of gene therapy;
however, recent !ndings, together with the data presented here, sug-
gest that more research is necessary to identify the temporal dynamics
and extent of in"ammation upon AAV delivery, its impact on the
safety and ef!cacy of ocular gene therapy, and ways to use this knowl-
edge to improve future therapeutic applications.
MATERIALS AND METHODS
Animals
Cynomolgus monkeys (Macaca fascicularis) were treated and taken
care of at the Covance Preclinical Services test facility in Münster.
The study was approved by the local institutional ethics board and
conducted in accordance to GLP standards as de!ned by German
GLP monitoring authorities, as well as in compliance with U.S.
Food and Drug Administration (FDA) GLP regulations. The age of
animals ranged between 2 and 5 years; the weight of animals was be-
tween 3.0 and 15.0 kg in males and 2.0 and 6.0 kg in females before
treatment. An animal health assessment was performed by a quali!ed
veterinarian before the start of the pre-dose phase to con!rm the suit-
ability of each animal for the study. The animals were not pre-
screened for pre-existing anti-AAV8 antibodies. They were assigned
to two studies: 22 animals to a 90-day study and 12 animals to a
28-day study (Table 1). Animals were regularly assessed by clinical
observation, monitoring of food consumption and body weight,
and ophthalmic examination (fundus and slit lamp examination,
fundus photography, scanning laser ophthalmoscopy, OCT, and
angiography). All animals were fasted overnight before scheduled
surgery and necropsy. Before exsanguination, animals received an
intramuscular injection with ketamine hydrochloride followed by
intravenous sodium pentobarbitone.
Surgery
Before surgery, periorbital regions were thoroughly cleaned with po-
vidone iodine, sterile surgical drapes were applied, and a pediatric lid
speculum was applied to left eye. A temporal canthotomy was applied
to facilitate access where necessary. Three sclerotomies were made
1–2 mm posterior to the limbus after transillumination con!rmed
the location of pars plana. The inferotemporal port was used to !x
a perfusion cannula. A pars plana vitrectomy was performed, and
4.0 mg/0.1 mL triamcinolone acetonide (preservative-free formula-
tion) were used to visualize vitreous or posterior hyaloid membrane
where appropriate. Localized retinal detachment was induced
through injecting 50 mL of BSS (Alcon) in the subretinal space using
a 41G cannula (DORC 1270.EXT). A total of 200 mL of vector solution
was injected subretinally or intravitreally to achieve the designated
dosing. The surgery was performed the same way in the clinical trial
with two exceptions: no canthotomy was necessary in patients, and all
sclerotomies were sutured in the clinical trial, but not in the animals,
in which additional irritation due to sutures would have caused more
oculodigital manipulation.
Dosing
The high-dose group animals received a total of 1 ! 1012 vg, and the
low-dose group animals received 1 ! 1011 vg. Subsequent to surgery,
subconjunctival cefuroxime (125 mg) and dexamethasone (4 mg)
were administered to the operated eye. Postoperative local treatment
Figure 4. Differential Gene Expression in Primate Retina following
Subretinal Gene Therapy
Expression profile from whole retina comparing samples from sham-injected ani-
mals versus animals from the high-dose group. Upregulated genes (red) are pre-
dominantly associated with the inflammatory Th1 pathway.
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included eyedrops 3 times a day for one week: Dexamytrex, Dexa-
Gentamicin, and Pred Forte (1% prednisolone). Systemic immuno-
suppression in the form of prednisone at 1 mg/kg (intramuscular)
was administered from day 2 until day 5.
Vector and Vehicle
The AAV8 vector (expressing the human CNGA3 cDNA sequence
and driven by the cone-speci!c human arrestin 3 [0.4 kb] pro-
moter21,22) was produced according to GMP guidelines by Atlantic
BioGMP in Nantes, France. The manufacturing process of the vector
relied on a transient double-transfection protocol of an HEK293
Master Cell Bank (MCB) fully characterized according to the Euro-
pean Pharmacopeia. Both plasmids were produced from two high-
quality characterized E. coli MCBs (DH10B strain). Following
expansion, the HEK293 cells were seeded in CellStacks 10 chambers
for the double-transfection step. The transfected cells and superna-
tant were then harvested in a BioProcess Container, and the lysate
was clari!ed by low-speed centrifugation. The cell pellet was dis-
carded and the supernatant was PEG-precipitated overnight at 2!C
to 8!C and then stored frozen at a temperature%"70!C. After thaw-
ing, the product was treated with Benzonase to digest nucleic acids
and puri!ed by two rounds of Cesium chloride gradient ultracentri-
fugation, followed by a tangential "ow !ltration step for dia!ltration
and concentration. After formulation in vehicle (BSS [Alcon] with
0.001% Kolliphor P188 Micro [Sigma]), the vector was stored at a
temperature %"70!C until use.
Histology
Eyes were !xed in 4% paraformaldehyde for 24 hr at 5!C ± 3!C. After
!xation and removal of cornea, iris, and lens, the eyecup was
Table 3. Genes Overexpressed in Treated Animals with Inflammation versus Sham-Injected Animals
Pattern Recognition Receptor Pathways
FC p Value FDR of 0.2Symbol Function
Toll-like Receptor Pathway
1 IRF5
member of the interferon regulatory factor (IRF) family of transcription factors,
responsible for activation of genes encoding key pro-in"ammatory cytokines
2.0 0.0001 signi!cant
2 TRAF3
member of the tumor necrosis factor (TNF) receptor-associated factor (TRAF)
family, a key regulator of non-canonical nuclear factor kB (NF-kB) signaling
1.4 0.0378 signi!cant
3 IRAK1
member of the interleukin-1 receptor-associated kinase (IRAK) family; the
phosphorylation of IRAK1 leads to subsequent activation of NF-kB and mitogen-
activated protein kinase (MAPK) pathways
1.1 0.0246 signi!cant
RIG-like Receptor Pathway
4 LGP2 member of the RIG-I-like receptor family, activating downstream interferon signaling 3.2 0.0024 signi!cant
Nod-like Receptor Pathway
5 AIM2
member of the pyrin family that serves as a cytosolic sensor for double-stranded
DNA and a component of in"ammasome
2.1 0.0001 signi!cant
6 PYCARD
encodes for apoptosis-associated speck-like protein (ASC), which in association
with caspase-1, forms NLRP3 in"ammasome
2.2 0.0215 signi!cant
7 Casp1
member of the cysteine-aspartic acid protease (caspase) family; sequential
activation of caspases plays a central role in the execution phase of cell apoptosis
1.9 0.0268 signi!cant
Cytokine Signaling and Other
88 CXCL10
member of the CXC subgroup of cytokines that binds to CXCR3 and plays pivotal roles in
the chemotaxis of in"ammatory cells, being involved in Th1-oriented immune responses
19.3 0.0130 signi!cant
9 CXCR4 a-chemokine receptor speci!c for stromal-derived-factor-1 2.2 0.0386 signi!cant
10 STAT1
member of the signal transducer and activator of transcription (STAT) family that
mediates cellular responses to interferons, cytokines, and other growth factors
3.5 0.0024 signi!cant
11 APOBEC3G component of innate antiviral defense system 2.1 0.0167 signi!cant
13 MX1
interferon-induced dynamin-like guanosine triphosphatase (GTPase) that participates in
cellular antiviral response by antagonizing the replication of viral RNA and DNA
2.2 0.0303 signi!cant
14 CTSB cathepsin B, a lysosomal cysteine protease that participates in intracellular proteolysis 1.6 0.0110 signi!cant
15 CD40 receptor on antigen-presenting cells, mediating a variety of immune responses 1.6 0.0158 signi!cant
16 IFIH1
encodes for MDA5, an innate immune receptor that acts as a cytoplasmic sensor of viral
nucleic acids
2.1 0.0092 signi!cant
15 L0C708080
cathepsin S, a lysosomal cysteine proteinase participating in degradation of antigenic
proteins
2.1 0.0152 signi!cant
FC, fold change; FDR, false discovery rate, as described by Benjamini and Hochberg.23
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dehydrated in ascending concentrations of sucrose (10%, 20%, and
30% each for 2 hr) diluted in 0.15 M PBS. Then, the eyes were
embedded in OCT and frozen in dry-ice-cooled isopentane (1 hr).
Eye cryosections (20–40 mm) were made from the nasal to the tempo-
ral aspect in the sagittal direction and mounted on SuperFrostPlus
glass slides.
qRT-PCR
RNA was extracted from 40 mm cryosections of treated eyes of the 12
monkeys in the 28-day study. Care was taken to select sections
traversing the treated area in every animal. Using a sterile scalpel,
the tissue was scraped off the slide and RNA was extracted after Pro-
teinase K digestion through silica-membrane spin column technique
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Figure 5. Retinal Immunohistochemistry Suggests Adaptive Cellular Immune Response in Eyes Treated Subretinally
Left panels show an eye treated with high-dose (1! 1012 vg) AAV8 injection; right panels show the vehicle-treated control. (A–D) Staining for microglia andmacrophages with
ionized calcium-binding adaptor molecule 1 (IBA1) shows marked response in the treated eye. (E–H) CD8+ cytotoxic T cells are evident in the AAV-treated eye, but not after
surgery with vehicle. (I–R) Antigen-presenting cells are observed in the AAV-treated eye, as are CD20+ B cells (S–V). Scale bar, 50 mm.
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(RNeasy FFPE kit, QIAGEN). Concentration and quality of eluted
RNA were analyzed by In!nite 200 NanoQuant (Tecan) and Bio-
analyzer 2100 (Agilent); RNA was deemed of suf!cient quality
when the RNA integrity number (RIN) was above 7. Immediately af-
ter extraction of RNA, concentration differences were equalized, and
reverse transcription was performed with the RT2 First Strand Kit
(QIAGEN) to prevent loss of RNA due to degradation. The cDNA
was stored at !20"C until further processing. qPCR was conducted
Figure 6. Activation Assays of PBMC Fractions
CD69 expression levels as surrogate markers for activa-
tion were quantified in PBMC subgroups CD3+/CD4+,
CD3+/CD8+, CD45+/CD19+, and CD45+/CD56+ either
spontaneously or after exposure to a dose range of AAV8
particles before and after treatment in three human pa-
tients. Two of three patients show marked changes in the
activation pattern of cytotoxic T cells (CD3+/CD8+), with a
peak 30 days after surgery. Different levels of sponta-
neous activity across time and across cohort demon-
strate inter- and intraindividual variability. Absolute peaks
of reactivity can be observed at different dilutions due to
the non-linearity of the antigen-leukocyte response.
using the 96 gene Rhesus Macaque PCR Array
(RT2 Pro!ler PCR Array, QIAGEN) in a
CFX96 C1000 Touch Thermal Cycler (Bio-
Rad). The PCR cycling conditions were as fol-
lows: 10 min of 95"C, followed by 40 cycles of
15 s at 95"C and 1 min at 60"C, followed by a
melt curve program at the end of each assay.
Array quality was controlled by the following
criteria: (1) for PCR array reproducibility, the
average Ct of the array built-in PPC (positive
PCR control) was 20 ± 2, and no two arrays
had an average PPC Ct > 2 from each other,
indicating that no ampli!cation-inhibiting fac-
tors were present; (2) no inhibition of reverse
transcription was determined by the average
of the built-in RTC (reverse transcription con-
trol) ! average PPC % 5; and (3) no genomic
DNA contamination was determined by a Ct
of genomic DNA control (GDC) > 35. Data
analysis was done by the DDCt method, in
which every gene of interest (GOI) was normal-
ized to the arithmetic average of expression of
selected housekeeping genes (HKGs) using the
following formula: DCt = Ct
GOI ! CtAVG HKG.
The following HKGs were used for normaliza-
tion: b-actin, glyceraldehyde-3-phosphate de-
hydrogenase, and ribosomal protein L13A. To
compare expression of genes across the dose
groups of animals, the DDCt for each gene
was calculated as DDCt = DCt (dose group) !
DCt (control group). The fold change is then ex-
pressed as 2(!DDCT). The p values are calculated
based on Student’s t test of the replicate 2(!DDCT). The false discovery
rate associated with multiple testing of expression data was controlled
for by the false discovery rate method published by Benjamini and
Hochberg.23
ELISA
A sandwich-ELISA strategy using an ELISA kit designed for titra-
tion of AAV8 particles (Progen, Germany) was applied to detect
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anti-AAV8 antibodies. The microtiter strips with AAV8-speci!c
antibodies from the kit were pre-incubated with clinical-grade
AAV8. Plasma samples collected from each animal before and at
days 1, 2, 7, 28, and 90 after surgery were then tested, and anti-
drug antibodies (ADAs) were quanti!ed via an enzyme conjugate
of a rabbit-anti-NHP antibody (MP Biomedicals). An anti-AAV8-
biotin-conjugated antibody, together with streptavidin peroxidase,
was used as positive control, with both being added into the
AAV8 titration strips. Once the substrate solution was added, the
color reaction was measured photometrically at l = 450 nm. To
avoid false negatives, plasma samples were diluted serially (1:5,
1:25, and 1:125).
Immunohistochemistry
Sections were left to dry at room temperature for 30 min and then
rinsed three times with PBS for 1 min (washing step). Sections were
blocked with 10% donkey serum in PBS + 0.1% Triton X-100 for
1 hr, followed by the same washing step. Primary antibody was
incubated for 1 hr at room temperature, followed by another
washing step and application of secondary antibody for 1 hr at
room temperature. The following antibodies were used: anti-human
CD8 (1:500, AbD Serotec, MCA1226T), anti-HLA-DR (major
histocompatibility complex class II [MHC II], 1:500, Abcam,
ab136320), anti-Iba1 (1:700, Wako, 019-19741), CD20cy (1:500,
Dako, M0755), anti-human HLA ABC (MHC I, 1:500, AbD Serotec,
136320), anti-F4/80 (1:250, Abcam, ab15285), donkey anti-mouse
IgG H&L (1:1,000, Abcam, ab150105), and donkey anti-rabbit
IgG H&L (1:1,000, Abcam, ab175470). After three rinses with
PBS, the sections were mounted with an antifade reagent containing
nuclear stain DAPI (Prolong Gold, Molecular Probes). Images
of immunostaining were taken using an Axio Imager Z1 micro-
scope (Zeiss, Oberkochen, Germany), and processed using Fiji
(v.2.0.0-rc).
Patients
The three patients (two male and one female) were diagnosed with
complete achromatopsia, and homozygous, disease-causing muta-
Figure 7. Virtual Cross-Sectional OCT Imaging
The treated retina (right) shows hyper-reflective spots
(white arrowheads) two weeks after surgery compared to
the untreated retina (left). Baseline imaging shows sym-
metric pre-existing foveal atrophy in this achromatopsia
patient before surgery (top panels). Middle panels show
the same area two weeks (14 days) after surgery to one
eye (right panel). Six months (180 days) after surgery
(lower panel), all hyper-reflective spots have resolved.
However, some degree of structural loss can be seen that
is not evident in the untreated contralateral eye.
tions in CNGA3 were con!rmed by a certi!ed
reference laboratory (CeGaT, Tübingen). Pa-
tients underwent the procedure after written
informed consent was given and were followed
up according to the approved trial protocol (ClinicalTrials.gov:
02610582; see also Supplemental Materials and Methods) approved
by the local institutional ethics board. All patients in this !rst dosing
group received 200 mL containing 1 ! 1010 vg of the clinical-
grade vector rAAV8.hCNGA3. Safety assessments included clinical
and ophthalmological examinations (including OCT imaging) at
screening, directly after surgery, and 1, 2, 3 ± 1, 14 ± 3, 30 ± 5,
90 ± 7, and 180 ± 7 days after surgery. All patients in the
study received a prophylactic regimen with oral prednisolone at
1 mg/kg as per study protocol (from day 1 until day 19, followed
by tapering off as deemed appropriate by the investigator).
Assessment of Cellular Immune Response in Patients
Blood samples were taken in all patients at screening and 30 ± 5,
90 ± 7, and 180 ± 7 days after surgery to isolate PBMCs and
test activation potential upon stimulation with AAV8 in PBMC
subpopulations, as previously described.24 Brie"y, 120 mL of
heparinized blood were drawn from subjects, and PBMCs were
isolated by centrifugation through Ficoll-Hypaque gradient within
24 hr. In previous studies, we showed that within this time, interval
cells are still viable and reliable, and reproducible results without
signi!cant changes can be obtained.25,26 PBMCs were adjusted to
1 million cells/mL (5 ! 105 cells/well) in RPMI 1640 medium
supplemented with 25% decomplemented autologous serum and
gentamycin. PBMCs were incubated with medium only (sponta-
neous activity) or with serial dilutions of clinical-grade AAV8
vector (1:500, 1:5,000, 1:50,000, or 1:500,000) for 24 hr and then
assessed for subgroup identity and CD69 expression levels as a
surrogate marker for activation. Antibody cocktails were used for
the demonstration of activated PBMC subpopulations (activated
CD4+ T cells, FastImmune CD4/CD69/CD3; activated CD8+
T cells, FastImmune CD8/CD69/CD3; activated CD19+ B cells,
FastImmune CD19/CD69/CD45; activated CD56+ natural killer
[NK] cells, FastImmune CD56/CD69/CD45; Becton Dickinson,
San Jose, CA). Furthermore, an IgG isotype control antibody
was used (BD Biosciences, San Jose, CA; Pharmingen). At least
10,000 PBMCs were counted. Quadrants were set based upon
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the isotype controls for each antibody. Results were expressed
as the percentage of CD69-expressing cells of the respective cell
types.
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4 Discussion 
 
With the data presented in the two papers we attempted to approach the immune response 
to subretinal AAV from the broadest possible angle. The chances and limitations of this 
approach will be discussed in the following order: The data presented in the paper 
“Humoral immune response after intravitreal but not after subretinal AAV8 in primates 
and patients” will be discussed in the first paragraph “Humoral immune response”. The 
clinical inflammation, the histology from the nonhuman primate retinas and the gene 
expression profile, all published in the paper “AAV can induce innate and adaptive 
immune response in the primate eye” will be discussed subsequently.  
 
 
  Humoral immune response  
 
To summarize the results of the humoral immune response, our study demonstrated that 
antibodies were generated in the intravitreal NHP group but not in the subretinal NHP 
group. No antibody formation was observed in the three patients. Antibody titers started 
to rise from day 7 onwards, with a peak on day 28 and declined towards day 90.  
These results mirror findings from other studies. It was already assumed that the 
intravitreal space somehow is more accessible to the immune system after two groups 
had described that AAV administered to the intravitreal but not the subretinal space can 
lead to antibody production which can prevent re-administration77, 78. It has been 
hypothesized that the enhanced biodistribution of viral vector over the blood and 
lymphatic tissue after intravitreal administration could serve as an explanation110.   
In contrast to the results of the mentioned studies, subretinal injections of rAAV2 
expressing CNGB3 (in cynomolgus monkeys) showed a dose-dependent antibody 
formation111, suggesting that an antibody reaction after subretinal AAV delivery is 
possible if a certain threshold is exceeded. Further support for this theory stems from the 
observation of a dose dependent humoral immune response after subretinal delivery in 
NHPs in a study by Vandenberghe et al. and in another study by Ramachandran et al. 
(although not as prominent as after the intravitreal application)51, 112.  
However, an antibody reaction in the subretinal high dose group would not necessarily 
mean that the assumption of a superior immune privilege in the subretinal space would 
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have to be suspended, it could also simply represent a reflux through the retinotomy into 
the intravitreal space. 
In this context it has to be noted that in our study antibody formation in the subretinal 
high dose group can not be completely ruled out as some values in this group are missing. 
These missing values could not be calculated because they exceeded the range of the 
assay. Nevertheless, an antibody reaction in the subretinal high dose group of the NHP 
(1x10^12vg) would not have had direct implications for the human trial as the highest 
dose planned in the clinical trial corresponds to the low dose group of the NHP preclinical 
trial (1x10^11vg).  
Concerning the question of relevance, it has to be kept in mind that the rising antibody 
titers in our study did not correlate with clinical findings in the ophthalmic assessment. 
For instance, the intravitreal group showed the highest rise in antibody titer but the lowest 
clinical severity score. Puzzlingly, in our results high antibody titers therefore could not 
be correlated with inflammation in the eye.  
But, as studies have shown that pre-existing humoral immunity is able to reduce 
therapeutic efficacy of ocular or systemic gene therapies 77, 113, clinical relevance could 
arise in the situation of re-administration of vector.  
Another limitation to this study is the lack of absolute thresholds for the level of 
significance of specific titer values. As ELISA values are not comparable between 
different studies it is difficult to judge which change of titer is to be deemed relevant.  
Further, titers showed variability in the sham injected group over the observation period, 
suggesting the occurrence of normal fluctuations in titer and/or test-retest variability of 
the assay. It is possible that the rise of antibody titer observed in some animals are in fact 
fluctuations of the titer that arise from the contact with wtAAV8 as wtAAV8 was 
originally isolated from and is commonly found among macaques114. High 
seroprevalence was also seen in our study. 90% of the monkeys showed pre-treatment 
antibody titers against AAV8. Interestingly, the antibody reaction of the two seronegative 
animals did not differ from the other animals.  
Another limitation of the study is the absence of technical replicates in the ELISA assay. 
Instead, the titers were calculated using the slope of a dilution sequence. 
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Finally, the study’s significance is limited by the small number of animals in each group 
and the presumable differences in antibody reaction between the monkeys and the human 
immune system. 
In summary, despite the mentioned limitations, our results suggest that AAV capsid 
antigen are processed by the adaptive immune response leading to the formation of 
specific antibodies. The histology data from the NHP, with infiltrating antigen presenting 
cells in the retina supports this thesis and further proposes the retina as a possible place 
of antigen presentation. These findings are of high value to the developers of ocular AAV 
mediated gene therapies in general and especially to the ones that use the intravitreal 
approach. These currently include AAV gene therapy studies for X-linked Retinoschisis 
(XLRS) or AMD115, 116. 
 
 
  Ocular inflammation following AAV 
 
4.2.1 Ocular inflammation in non-human primates 
 
Clinical signs of inflammation like cells in the anterior or posterior chamber of the eye, 
were observed in all NHP groups. While cells in the anterior chamber peaked at day three 
and gradually declined afterwards, intravitreal cells persisted at low levels.  
The subretinal control group which received a sham injection with balanced salt solution 
(BSS) also showed a limited number of cells at a lighter scale than the other groups 
indicating that some degree of inflammation is due to the surgical procedure by itself.  
This kind of ocular inflammation following the application of subretinal or intravitreal 
AAV has been observed in several other preclinical and clinical studies. 
Ye et al. described a dose dependent inflammation of the anterior and posterior segment 
with vitreous cells that persisted over the full observation period (90 days) after 
intravitreal application of rAAV2tYF (a modified version of AAV serotype 2) for X-
linked juvenile Retinoschisis (XLRS).111 These results were reproduced in a second study 
by the same authors for a subretinally applied vector based on the AAV 2 serotype 
(rAAV2tYF-PR1.7-hCNGB3 to treat Achromatopsia).117 Both studies used a capsid 
containing three tyrosine-to phenylalanine mutations to enhance transduction efficacy. 
The implications for immune reactivity of the capsid are unknown. 
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One animal in the CNGB3 study developed a severe ocular inflammation 
(endophthalmitis) at day 5 and had to be sacrificed subsequently. Microbiological tests 
showed no bacterial growth in cytology or aerobic culture. These findings could suggest 
a test-item related immune response but Ye et al. argued that an occult bacterial 
endophthalmitis could not be ruled out completely. In all other vector-injected animals of 
the study histological examination showed minimal mononuclear cell infiltrates around 
retinal blood vessels.  
Dose dependent ocular inflammation in NHP has also been reported by two other groups 
(AAV vectors expressing GFP): Vandenberghe et al. and Ramachandran et al. both 
showed that high dose subretinal AAV8 can lead to focal retinal inflammation51, 112. 
Ramachandran et al. additionally reported an upregulation of GFAP expression as a 
marker of glial activation. Vandenberghe et al. further described retinal thinning and 
disrupted retinal architecture as well as a T cell mediated transgene toxicity against GFP 
but no T cell response against the AAV8 capsid. The group hypothesized that the 
transgene immunity against GFP could be attributed to the fact that GFP is a foreign 
protein (derived from jellyfish) and thus potentially immunogenic in the NHP.  
Although this reflects the situation of patients with null-mutations receiving gene addition 
therapy (which would lead to expression of a ‘novel’, if human, protein), transgene-
directed immune response has not yet been described in human clinical trials (including 
in patients with predicted null mutations).  
 
 
4.2.2 Ocular inflammation in patients 
 
The patients of our study did not present any signs of inflammation in the clinical slit-
lamp examination. It has to be noted though, that one patient presented hyper-reflective 
spots in the OCT. Although multiple theories exist for the pathological correlation of 
these spots, the most likely correlate are activated microglia or other infiltrating immune 
cells118, 119. Our observation in the NHPs support this interpretation. Under steroid 
treatment these spots resolved completely.  
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In the pivotal phase III trial for voretigene neparvovec (AAV2-hRPE65v2), 6 out of 20 
patients were reported to have presented mild signs of ocular inflammation. All signs of 
inflammation resolved under concomitant steroid treatment30.  
A more vigorous inflammatory response in a patient has been reported by Bainbridge et 
al. in 2015. In their RPE65 trial, 5 out of 8 high dose group patients responded with signs 
of clinical inflammation and one patient showed a persistent reduction in visual acuity 
together with a rise of neutralizing antibodies around week 4 and a slight increase of 
circulating T cell against the AAV2 capsid1. 
Similar to the findings by Bainbridge et al., Dimopoulos et al. reported recently that in 
their AAV2-mediated choroideremia trial one out of six patients developed a serious 
adverse event after the injection of subfoveal AAV2.REP1. The patient presented a 
localized intraretinal immune response (hyperreflective spots), that resulted in a decline 
of vision and loss of outer retinal structures2. It is yet unclear why some patients reacted 
with vigorous inflammation and others did not.  
 
 
  Histology 
 
In the hematoxylin and eosin staining of the NHP retinal sections of our 28 day study, 
mononuclear cells infiltrations were observed in the subretinal and choroidal space. These 
infiltrations were mostly found in the high dose group. Less pronounced infiltrations were 
predominantly found in the low dose group, but also found in the sham injected control 
group and could thus represent incidental background findings and/or be due to the 
surgical procedure itself (as opposed to the AAV). Interestingly, no histological 
abnormalities were found in the animals that were sacrificed after 90 days suggesting a 
transient nature of the immune reaction. 
In order to further define the nature of the infiltrating immune cells found after 28 days, 
immunohistochemistry was performed on neighbouring sections of the same eyes. A 
technical limitation to overcome was, that the eyes had been fixed in 4% PFA leading to 
some difficulties in finding of the optimal staining protocol. As fixation in PFA is known 
to mask antigens and impair epitope binding, spleen tissue of the same monkeys was cut 
and stained beforehand with the same protocol to serve as a positive control (especially 
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for epitopes relating to immune competence). The sham-injected eyes of the control group 
served as the negative control.  
 
4.3.1 Iba1 
 
Iba1 (ionized calcium-binding adapter molecule 1) was used as the most reliable staining 
marker for microglia120 Retinal microglia in the normal retina populate the plexiform 
layers121. They are stationary phagocytic sentinel cells that have migrated into the retina 
during embryonic development and early postnatal phase. In the retina, microglia are 
responsible for the control of retinal homeostasis and the phagocytosis of cell debris. 
Therefore, they inhibit a variety of surface proteins and long motile processes to scan 
their local environment122. Age-related and multifactorial retinal diseases as well 
inherited degenerative retinal diseases are associated with an activation of microglial 
cells123-125. In the case of activation microglia start to proliferate and change their 
appearance from a ramified form into an amoeboid form that migrates from the plexiform 
layer into other layers and to the site of damage121. 
When comparing the treated eye to the sham injected eye, staining with Iba1 showed a 
marked increase in signal. Also, the distribution pattern differed and treated eyes showed 
Iba1 signal not only the plexiform layer, but also the nuclear layers of the retina. 
The signal increase was restricted to the area of treatment.  
Microglia represent the cellular innate immune response in the retina. The activation we 
observed could therefore be due to the recognition of either vector particles themselves 
or a change of microenvironment that leads to proliferation of microglia. It is improbable 
that the activation visible 30 days after treatment is attributed to the temporary retinal 
detachment as the slides were compared to eyes that received a sham-injection of the 
same volume with BSS. The fact that the Iba1 signal is observed in the expected location 
(plexiform layers and after activation in all layers) further supports the thesis that 
microglia are indeed observed.  
Microglial activation is regulated by several inhibitory factors expressed by other cells of 
the retina to maintain the balance between the beneficial phagocytic functions of the 
microglia and possible auto-destructive responses that damage neurons126, 127.  
Form the histological observation of activation we cannot tell whether this balance is 
compromised. The activation of microglia could also represent the reestablishment of the 
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homeostasis after some sort of damage caused by the treatment. What can be concluded 
from the observation, though, is that homeostasis is at least temporarily impaired leading 
to an activation of microglia. 
 
4.3.2 MHCI 
 
As mentioned in the introduction, the classic pathway of innate antiviral defence 
mechanisms of host cells leads to the presentation of viral particles via MHCI molecules, 
which -in turn- enable cytotoxic CD8 T cells to kill the virus infected cell. 
Staining with MHCI gave a strong signal of the RPE and some singular cells in the retina 
that were not found in the sham injected eyes.  
In the central nervous system MHCI is generally expressed only by glia cells and not by 
neurons in order to protect neuronal tissue from cytotoxic T cell responses. Nevertheless, 
this view has been challenged by the observation that in some special inflammatory 
situations in vivo and under artificial conditions in vitro neurons are able to present 
MHCI128. However, this has not yet been described for the adult retinal cells which is 
supported by our observation that did not include MHCI upregulation in retinal neural 
cells. 
The RPE cell, as a phagocytotic cell is however expressing MHCI constitutively 
represented on our slides by a strong signal of MHCI over the RPE layer129. 
The MHCI positive cells observed within the retinal layers could therefore either 
represent microglia or other immune competent cells that have infiltrated the neural 
tissue. 
 
4.3.3 MHCII 
 
MHC II is expressed by antigen presenting cells (APC). In the retina these cells include 
microglia and macroglia, from which the latter can be subdivided into retinal astrocytes 
and Müller cells121. The RPE cells are known to express MHCII after stimulation with 
INF-g and can therefore also be regarded as antigen presenting cells130.  
Immunohistochemistry of the AAV treated slides showed MHCII positive cells in the 
retina and in the subretinal space. Double-staining with Iba1 (unpublished images) 
showed that some cells co-express MHCII and Iba1 but not all cells do. Although no 
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evidence is at hand to the nature of these MHCII positive cells that do not co-express 
Iba1, they could, besides the other mentioned APCs, partly represent CD20 positive B 
cells, which were also found in the retina but could not be co-stained with MHCII for 
technical reasons. 
 
4.3.4 CD8 
 
CD8 positive cells that were found in the retina most likely represent infiltrating cytotoxic 
T cells. Capsid specific T cells have already been observed after AAV mediated gene 
transfer to hepatocytes81. In the eye they have not been described following AAV 
treatment but in models of uveitis like Experimental autoimmune uveoretinitis (EAU) 
CD4 as well as CD8 positive T cells are the main mediators of inflammation131.  
But CD8 positive cells could also carry out regulatory function. Although the main 
protagonist of regulatory T cells are CD4+, CD25+, FoxP3+ T cells, CD8+ regulatory T 
cells have also been described to be part of the immune suppressive mechanisms of the 
eye132. However, these cells did not stain for CD4, markers for regulatory activity 
(CD103b, FoxP3) or INF-g as marker for a TH1 response. 
 
4.3.5 CD20 
 
Interestingly staining for CD20 showed that infiltrating B cells seem to be involved. This 
is another parallel to the pathological observations of EAU in a monkey model where 
infiltrating B cells have been described to be the main infiltrating lymphocyte133. In 
uveitis, B cells play a key role in the inflammatory process which is further evidenced 
also by the beneficial treatment effects of Rituximab, a CD20 antibody therapy133, 134.  
Tissue infiltrating B cells play a role in various autoimmune diseases, especially 
neurological autoimmune disorders135. They also play an important role as tumor 
infiltrating lymphocytes and take part in the rejection of renal allografts136, 137. Of 
relevance, they have also been observed in local immune infiltrations after intramuscular 
AAV1 gene therapy138. 
The function of the B cells in the retina is unclear. As reviewed by Smith et al. for non-
infectious uveitis, there are multiple potential mechanisms by which B cells can initiate 
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or perpetuate inflammation in the eye. However, they can also contribute to immune 
suppression mediated by a subset of B cells called B regulatory cells139.  
The mere presence of B cells in the retina strongly encourages the idea of an antigen 
specific immune response mechanism. The induction of antibodies observed is in line 
with this theory. Unfortunately, no PBMC (peripheral blood mononuclear cell) activation 
assay data is at hand for the NHP. In the patient PBMCs no activation of CD19+ B cell 
after stimulation with AAV8 was observed. 
 
 
  Expression Analysis 
 
For the gene expression analysis, retinal tissue samples from the high dose group were 
compared to samples from the sham injected animals. The data showed enhanced gene 
expression of markers involved in the innate anti-viral immune response in the samples 
from the high dose group vs the sham injected animals. These included markers of the 
three major pattern recognition receptor pathways (TLRs, RIG-like receptors and NOD-
like receptors) as well as markers involved in an INF-g mediated TH1 response like the 
chemokine CXCL10.  
Although TLR9 and Myd88 were not significantly upregulated, their downstream 
signalling molecules IRF5 and TRAF3 were. As mentioned in the introduction, the 
TLR9-Myd88 pathway has been shown to be part in the recognition of AAV and 
responsible for staging a Th1 mediated immune response. Although no answer is at hand 
why only some of these downstream molecules are overexpressed and others are not our 
findings could still be implicating that the TLR9 pathway is activated. 
Other markers that were found upregulated in the high dose group have not yet been 
associated with AAV but could be interesting targets for future investigations. LGP2 
(Fold change (FC) of 3.2, p value 0.0024) and AIM2 (FC of 2.1, p value 0.0001) are both 
sensor proteins for cytosolic dsDNA. LGP2, a DEHX box domain protein related to the 
RIG-I like receptors participates in the cellular response to cytosolic dsDNA140. Although 
the AAV genome traffics the cytosol via endosomes and is only released into the cells’ 
nucleus, it can be hypothesized that some DNA molecules may be recognised, making 
these cytosolic DNA receptors interesting molecules for future investigations on AAV 
immunity.  
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Absent in melanoma 2 protein (AIM2) is a member of the PYHIN protein family and 
another sensor for cytosolic dsDNA. AIM2 forms together with ASC and caspase1 the 
inflammasome and drives INF gene transcription105. ASC (FC of 2.2 p value 0.0215) and 
Caspase 1 (FC of 1.9, p value 0.0268) were also both overexpressed which strengthens 
the assumption that this pathway could be activated. 
The highest elevation (Fold change of 19, p value: 0.013) was shown for CXCL10. This 
chemokine is induced by INF-g and attracts macrophages, T-cells and NK cells. It is 
further known to play a pivotal role in mediating the influx of effector T cells into the 
CNS in a number of viral infectious diseases and can be expressed by glia and     
neurons141, 142  
Taken together, this data suggests that the subretinal treatment with AAV8 leads to an 
activation of the innate immune response in the retina.  
Although INF-g expression was not detected directly, the upregulation of several 
pathways connected to the release of INF-g and the finding of T and B cells in the retina 
are highly suggestive of an INF-g mediated TH1 response. Although INF-g release is 
generally restricted to T cells and NK cells, in some situations it can also be expressed by 
microglia143. As the gene expression analysis data results from the whole retina tissue und 
not a specific cell line no conclusive answer to the question can be drawn from these 
results. In the future cell culture experiments might be able to shed more light on the 
actions of the different cells involved. 
Limiting factors of the assay are the low number of animals included (high dose n=3, 
control group n=4) and the fact that the tissues had been fixed with PFA before RNA 
isolation. Paraformaldehyde leads to chemical modification and fragmentation of 
RNA144. For this reason, formalin-fixed samples are often poor material for molecular 
biology applications. Especially long RNA molecules are prone to fragmentation 
resulting in an altered expression profile. But as Wiegers and Hilz described in 1971, the 
use of Proteinase K prior to extraction digests the ribonucleases that degrade RNA during 
the extraction process145. After several attempts the use of Proteinase K was found to be 
crucial in receiving good quality RNA. This finding is well supported by existing 
literature145-147. Our results on RNA quality assessments after isolation and prior to the 
qPCR experiment showed that our data offers a valid expression profile. 
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  Conclusion 
 
Multiple studies have shown that subretinal AAV meditated gene therapy can lead to 
inflammation of the eye. This immune response is in most cases a transient phenomenon 
that is manageable with steroid treatment. But individual cases of clinically significant 
immune response effecting visual function illustrate that knowledge about the 
immunologic potential of AAV in the eye is not only essential to enhance safety but might 
also increase the efficacy of future therapies.  
Our data suggest that certain amounts of subretinal AAV are able to overcome the anti-
inflammatory immune privilege of the eye. This thesis is supported by gene upregulation 
of markers of the innate antiviral immune defense, the activation of microglia as the 
“immunological watchdogs”121 of the retina and the infiltration of cells of the adaptive 
immune system like CD8+ T cells and CD20+ B cells. The role of these cells in the retina 
can only be hypothesized but CD8+ cytotoxic T cells are known to play a major role in 
antiviral immunity against AAV transduced cells81, 89. It therefore seems likely that they 
adopt a similar function in the retina. The fact that NHP did not present histological signs 
of inflammation after 90 days matches the clinical observation of a transient immune 
reaction. This could be attributed to the anti-inflammatory features of the eye that in most 
cases are able to contain the immune response. It remains unclear, though, whether 
specific tolerance is induced or if the decline of inflammation is a sign of effective 
clearance of the remaining AAV vector particles. If the latter is true, future studies would 
have to determine if the immune response is only directed to free AAV8 particles or as 
well to vector transduced cells. As photoreceptors do normally not present antigens via 
MHCI, damage to these cells is probably only resulting as a side effect of activated 
infiltrating APCs that are not suppressed by the anti-inflammatory mechanisms of the 
eye.  
It has to be kept in mind that all NHP and all patients received concomitant steroid 
treatment. As the inflammation responded to steroid treatment this measurement seems 
to be justified. Future studies will have to show if alternative or additional anti-
inflammatory regimens could help to suppress the immune response even better. Care has 
to be taken when applying new anti-inflammatory drugs as studies have shown that the 
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immunomodulation is able to cause also unwanted detrimental effect to the tolerogenic 
properties of AAV148, 149. 
Limitations of the study include presumed differences between the human and nonhuman 
primate immune system, the limited timepoints, missing PBMC data from the NHP and 
missing antibody data for the 28 day NHP study.  
However, this study adds valuable information to the question how AAV is able to elicit 
specific immune responses in the subretinal space. This information might be able to 
guide future studies in enhancing safety and efficacy of the therapy.
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5 Summary 
 
 Introduction 
 
Adeno-associated viral (AAV) vectors are commonly used in ocular gene therapy for 
inherited retinal degenerations. They are known for their excellent efficacy in transducing 
retinal cells and their benign immune profile. However, the observation that subretinal 
AAV can lead to ocular inflammation highlights the importance to re-evaluate the 
immunogenicity of AAV.  
 
  Methods and material 
 
Cynomolgus monkeys (Macaca fascicularis) were treated with subretinal or intravitreal 
injections of AAV serotype 8. The high dose group received 1x10^12 viral genomes (vg) 
and the low dose group 1x10^11 vg. The control group received injections with vehicle 
only (balanced salt solution). Of the 34 animals included in the study, 12 were sacrificed 
after 28 days and 22 were sacrificed after 90 days. During the observation period, blood 
was taken at fixed timepoints for ELISA of antibodies directed against AAV capsid 
epitopes. After the inlife phase of the study, eyes were fixed in 4% PFA, embedded and 
frozen at -80°C. 20µm cryosections were subsequently used for expression profiling and 
immunohistochemistry.  
These data were compared to clinical observations from three patients treated with the 
same vector subretinally. OCT images were taken and peripheral blood mononuclear cells 
were isolated from patient blood at defined timepoints to be analysed for AAV specific 
reactivity.  
 
 Results 
 
The ELISA study of NHP derived blood samples showed an increase in anti-AAV8 titer 
at day 30 in the intravitreal high dose group but not in the subretinal high or low dose 
group. No antibody formation was observed in the three patients. Immunohistochemistry 
showed an inflammation of the NHP retina with activation of IBA1+ microglia and 
infiltration of CD8+ T cells and CD20+ B cells at 28 days following surgery. Expression 
analysis of the retinal tissue showed an upregulation of genes related to the innate antiviral 
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immune response and associated with the release of INF-g. None of the three patients 
showed clinically significant inflammation, but one featured hyperreflective  foci in OCT 
images one month after surgery, which disappeared following steroid treatment. PBMC 
analysis showed changes in the activation pattern of CD8+ T cells one month after surgery 
in 2 out of 3 patients. 
 
 Discussion 
 
The data presented in this study suggests the activation of the innate and adaptive 
immune response following AAV administration. This hypothesis is supported by the 
activation of markers of antiviral immune pathways (Toll like, RIG1 like and NOD like 
receptor pathways) and the increase of capsid specific antibodies as well as retinal 
infiltration of cells of the adaptive immune response. Future studies will have to 
determine the exact dynamics of the infiltrating immune cells and how this immune 
response can be effectively inhibited. 
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6 Zusammenfassung 
 
 Einführung 
 
Gentherapeutische Ansätze zur Behandlung erblicher retinaler Degenerationen basieren 
zum Großteil auf rekombinanten adeno-assoziierten Viren (AAV) als Vektor zur 
Transduktion der Netzhautzellen. AAV sind im Vergleich zu anderen viralen Vektoren 
bekannt dafür, dass sie bei guter Transduktionseffizienz gleichzeitig eine gering 
ausgeprägte Immunogenität aufweisen. Aufgrund sich mehrender Beobachtungen von 
Immunreaktionen auf AAV vermittelte Gentherapien in präklinischen und klinischen 
Studien wurde immanent, dass der bisherige Kenntnisstand zur Immunogenität diese 
Vektoren lückenhaft ist und einer umfassenden Klärung bedarf. Das Ziel dieser 
Doktorarbeit war über die Erforschung der Mechanismen auf molekularer und zellulärer 
Ebene die Tür in diese Richtung etwas aufzustoßen. 
 
 Material und Methoden 
 
Im Rahmen einer präklinischen Toxizitäts und Sicherheitsstudie wurden Javaneraffen 
(Macaca fascicularis) mit einem AAV8 vector entweder intravitreal oder subretinal 
behandelt. Unterteilt wurde in eine Hochdosisgruppe (1x10^12 virale Genomkopien 
(vg)), eine Niedrigdosisgruppe (1x10^11 vg) sowie eine Kontrollgruppe, welche eine 
gepufferte Kochsalzlösung erhielt. 12 Versuchstiere wurden über einen Zeitraum von 4 
Wochen, 22 Versuchstieren über einen Zeitraum von 90 Tagen nach Behandlung 
beobachtet bevor die Organentnahme durchgeführt wurde. Während des genannten 
Zeitraums wurden Blutproben entnommen und Antikörpertiter mittels ELISA Technik 
berechnet. Danach wurden die Augen in 4% Paraformaldehyd fixiert, in einem 
Gefrierschneidemedium eingebettet, und in 20µm Schnitten bei -80 C° eingelagert. Diese 
Schnitte wurden dann wiederum für immunhistochemische Färbungen und zur Erstellung 
von Expressionsprofilen genutzt. Diese Daten wurden verglichen mit klinischen 
Observationen dreier, mit dem gleichen Vektor subretinal behandelter Patienten. Hierzu 
wurden OCT Bilder und die in-vitro Reaktion peripherer Immunzellen auf den Vektor 
analysiert. 
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 Ergebnisse 
 
In den Vektor-injizierten Javaneraffen stiegen Antikörpertiter gegen des AAV8 Capsid 
um den Tag 30 nur in der intravitreal behandelten Hochdosisgruppe aber nicht in den 
subretinal injizierten Gruppen. In den Patientenproben waren keine Antikörperreaktionen 
sichtbar. Die immunhistochemischen Färbungen der Affennetzhäute fand sich bei den 
nach 4 Wochen getöteten Tieren eine entzündliche Infiltration von Immunzellen, unter 
diesen IBA1+ Mikroglia Zellen, CD8+ T-Zellen und CD20+  B-Zellen. In der RNA - 
Expressionsanalyse derselben Tiere zeigte sich eine Aktivierung von Genen für Signal 
und Rezeptormoleküle welche über die Aktivierung von INF-g an der angeborene 
Immunantwort gegen Viren beteiligt sind. Keiner der Patienten präsentierte klinische 
Zeichen einer Entzündung. Allerdings waren im OCT fokale Veränderungen der 
Netzhaut sichtbar, welche auf eine Prednisolontherapie ansprechend, daraufhin 
verschwanden. Die Analyse der PBMC zeigte eine Aktivierung von CD8+ T-Zellen nach 
einem Monat in 2 von 3 Patienten. 
 
 Diskussion 
 
Die in dieser Doktorarbeit präsentierten Daten zeigen die Aktivierung einer lokalen und 
systemischen Immunantwort. Die Hochregulierung von antiviralen Genen bestimmter 
Pathways (Toll like, RIG 1 like und NOD like receptor pathways) zusammen mit dem 
Anstieg von spezifischen Antikörpern suggeriert die Beteiligung der angeborenen sowie 
die adaptiven Immunantwort. Welche klinische Bedeutung die einzelnen Beobachtungen 
haben und welche Implikationen für die Weiterentwicklung okulärer Gentherapien 
müssen weitere Studien herausfinden. Dies ist ebenso wichtig für die Sicherheit von 
AAV-vermittelten Gentherapien in der klinischen Anwendung wie für die therapeutische 
Effizienz dieses Ansatzes. 
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